



HHS Public Access

Author manuscript

Anesthesiology. Author manuscript; available in PMC 2023 December 12.

Published in final edited form as:

Anesthesiology. 2022 January 01; 136(1): 10–30. doi:10.1097/ALN.0000000000004065.

Opioids and public health: The prescription opioid ecosystem and need for improved management

Evan D. Kharasch, M.D., Ph.D.¹, J. David Clark, M.D., Ph.D.², Jerome M. Adams, M.D.³

¹Department of Anesthesiology, Duke University School of Medicine, Durham, NC

²Anesthesiology Service, Veterans Affairs Palo Alto Health Care System, Palo Alto, CA;
Department of Anesthesiology, Stanford University School of Medicine, Stanford, CA

³Director of Health Equity, Purdue University, 20th U.S. Surgeon General

Abstract

While U.S. opioid prescribing has decreased 38% in the past decade, opioid deaths have increased 300%. This opioid paradox is poorly recognized. Current approaches to opioid management are not working, and new approaches are needed. This article reviews the outcomes and shortcomings of recent US opioid policies and strategies that focus primarily or exclusively on reducing or eliminating opioid prescribing. It introduces concepts of a prescription opioid ecosystem and opioid pool, and discusses how the pool can be influenced by supply-side, demand-side, and opioid returns factors. It illuminates pressing policy needs for an opioid ecosystem that enables proper opioid stewardship, identifies associated responsibilities, and emphasizes the necessity of making opioid returns as easy and common as opioid prescribing, in order to minimize the size of the opioid pool available for potential diversion, misuse, overdose, and death. Approaches are applicable to opioid prescribing in general, and to opioid prescribing after surgery.

Summary Statement:

Despite major restrictions on opioid prescribing, the opioid overdose crisis worsens. The prescription opioid ecosystem concept encompasses supply, demand, and the pool available for diversion. Emphasis is needed on facilitating opioid disposal and return to diminish the pool.

Status of the Problem

The current opioid crisis, emanating from inappropriate prescribing, marketing, diversion, and misuse of oral prescription opioids for acute and chronic noncancer pain,¹ has a staggering human and economic toll.^{2–4} In the U.S. there have been more than 450,000 opioid-related deaths over the past two decades, one quarter of which may be suicides.⁵ This cost the US economy more than \$2.5 trillion between 2015 and 2018, including an estimated \$700-\$1000B in 2018 alone – representing 3.4% of the US gross domestic product.⁶ Opioid

Address Correspondence to: Dr. Evan Kharasch, Department of Anesthesiology, Duke University School of Medicine, Box 3094, 905 S. LaSalle St, GSRB1 Room 2031, Durham, NC 27710 Tel.: 919-613-1154 evan.kharasch@duke.edu.

Dr. Kharasch and Dr. Adams have no competing interests. Dr. Clark has a consulting agreement with Teikoku Pharma USA (San Jose, California).

misuse and fatal overdose are not limited to the US,^{7–10} or to adults.¹¹ Moreover, the problem worsened during the COVID-19 pandemic, due primarily to illicit fentanyl and analogs.^{12–14} The influence of the COVID-19 pandemic on opioid overdose, whether due to illicit fentanyl abundance, disrupted prescription drug supply chains, increasing drug toxicity, social isolation, unemployment, worsening mental or physical health, or reduced access to emergency medical and drug treatment services, continues well into 2021.^{15,16}

The opioid crisis has multiple antecedents.^{17–19} It is grounded on the pain epidemic, currently the most prevalent (40–100 million US adults), disabling, and costly public health problem in the US, the societal costs of which exceed the annual combined costs of heart disease, diabetes, and cancer.²⁰ It is also grounded on the more debilitating subset of high-impact chronic pain, which impairs work outside the home, education, social activities, and simple self-care and daily living, which is suffered by 11 million US adults, and who use a disproportionate amount of health care.²¹ It is also grounded on the over-prescription and overuse of oral opioids, and in patients for whom they were not indicated or effective. Contributory also were avaricious and illegal marketing of prescription oral opioids, and economic stagnation, unemployment, poverty, lack of opportunity, social distress, and substandard living and working conditions in underprivileged areas of the country.^{22,23} The US Drug Enforcement Administration estimates that 163,683,029 schedule II prescriptions (retail cost \$ 11.8 billion) were filled for “acute pain” in 2017.²⁴ Overuse and misuse of prescription oral opioids and associated overdose was then followed by a rapid and fluid shift of the use- and supply-chain of abused opioids from medical to illicit (first heroin and then fentanyl) sources.^{25–27} Indeed, deaths in North America attributed to illicit fentanyl now outnumber those from heroin.¹⁹

The “opioid paradox” is that opioid overdose mortality has continued to increase despite steady reductions in opioid prescribing (Figure 1).²⁸ Overall opioid prescribing is decreasing, in both numbers of patients exposed and average doses prescribed (Figure 1).^{29,30} Opioid prescribing in the US initially quadrupled from 1999 to the peak in 2012,³¹ but has decreased 43% since then (from 81 to 47 prescriptions per 100 persons in 2020).³⁰ Nonetheless, average daily morphine mg equivalents have decreased more slowly, because the average supply per prescription continues to rise.³² Opioid use is still common, with 15% of the US population filling one or more opioid prescriptions in 2018.³² Despite the declining prescription numbers, overdose deaths have not declined, due to the increased use of heroin and illicit fentanyl.^{33,34}

There is inescapable public and practitioner awareness of the opioid crisis, extensively documented inappropriate outpatient oral opioid use and over-prescribing, innumerable federal, state, local, and institutional regulatory, legislative, and guidance restrictions on opioid prescribing, and billions of dollars invested to combat the opioid crisis over the past 5 years. Nonetheless, these approaches are failing to retard or reverse the epidemic of opioid-related fatalities. There has been some improvement, in that the number of Americans 12 or older who misused opioids decreased from 11.8 million in 2016 to 10.1 million in 2019,^{35,36} and the number who misused prescription pain relievers decreased from 11.5 million in 2016 to 9.7 million in 2019.^{35,36} In addition, the number who initiated prescription pain reliever misuse *each day* in 2019 (4400)³⁶ was less than in 2018 (5230).³⁷

Nevertheless, this still represents 1.6 million new misusers in just one year. Moreover, these small reductions represent a feeble response compared with the plethora of recently enacted restrictive countermeasures intended against opioid prescribing and misuse.

Furthermore, the opioid overdose rate is climbing (Figure 1). Nearly 50,000 Americans died of an opioid overdose in 2019 (137 per day), then a new record.^{38,39} This was a 3-fold increase from 16,600 overdose deaths in 2010,⁴⁰ and a 4-fold increase from the previous decade.⁴¹ Even worse, opioid overdose deaths spiked again in 2020, to 66,000 (181 per day, one every 8 minutes),³⁸ the highest number on record and the largest annual percentage increase in the past 20 years. Opioids now account for 74% of all fatal drug overdoses, increased from 63% in 2015.³⁸ Death rates continue to be driven primarily by overdose from synthetic opioids (mainly illicit fentanyl), which account for more than 2/3 of opioid overdose deaths.³⁹ Overdose due to prescription opioids has plateaued (Figure 1), but overdose death rates involving fentanyl and other synthetic opioids increased more than *10-fold* from 2013 to 2019,³⁹ and *more than doubled* between 2016 and 2020.³⁸ Most recently, synthetic opioid deaths increased 38% in the year ending May 2020,¹³ and continue to rise.³⁸ It is abundantly clear that present approaches to the opioid crisis are not succeeding.

Postoperative pain and opioids – the problem of variability

The seminal and intractable problem is inter- and intra-patient variability in postoperative pain and pain relief. Distinct and widely disparate trajectories of postoperative pain and recovery have been identified.^{42,43} Postoperative pain and opioid needs can be influenced by ethnic, racial, physiological, cultural, and religious factors, as well as by age, sex, comorbidities, fear, anxiety, prior pain history, coping style, drug interactions, genetics, health disparities, health literacy, preoperative opioid use, social support, and setting (inpatient vs outpatient surgery).⁴⁴ Considerable variability in postoperative pain and opioid consumption is a consistent finding. For example, across four common operations (laparoscopic cholecystectomy, hernia repair, hip replacement, knee replacement) and 103 hospitals, postoperative pain was common and highly variable (range 0-9 on a 10 point scale).⁴⁵ Among nearly 2400 patients across 12 surgical procedures there was 25-fold variability in the interquartile range of opioid pills taken after surgery.⁴⁶ After Cesarean section many patients took no or less than 5 opioid pills; while about 20% took all or nearly all of the approximately 30 pills prescribed at discharge,^{47,48} and after thoracic surgery nearly half took no or less than 5 opioid pills, while nearly 30% took all or nearly all.⁴⁷

Variability in postoperative pain and opioid use is accompanied by considerable variability in post-surgical opioid prescribing. Indeed, such variability is even greater for surgical than for medical conditions.⁴⁴ For example, in adults, after total knee arthroplasty, the interquartile range of post-discharge oral opioids prescribed to opioid naïve patients was 75-475 mg morphine equivalents, and the total range was 0-1500 mg.⁴⁹ In children, after the common outpatient operations tonsillectomy and hernia repair, post-surgical opioid prescribing is similarly highly variable.⁵⁰ This is reflected in numerous other procedures as well, in both adults⁵¹ and children.⁵² Variability is great even among members of the same surgical team, and between provider type. For example, after discharge from five common

inpatient surgical procedures, ranges of 6 to 72, 6 to 189, and 5 to 1000 opioid pills, equivalent to 30 to 600, 30 to 1600, and 25 to 1000 morphine milligram equivalents, were prescribed by attending surgeons, residents, and advanced care practitioners, respectively.⁵³ Variability in postoperative opioid prescribing is also influenced by surgeons' years of practice, credentialing, type of surgery, and geographic location.⁵⁴ Variability ranges from micro scale (within the same surgery service in just one hospital),⁵⁵ to macro scale (across countries and continents).⁵⁶

The Opioid Pool

A foundational element of the opioid crisis is the size of the unused opioid pool available for potential diversion, misuse, addiction, and overdose. The pool is fed by the over-prescription of oral opioids, including the aforementioned inappropriate outpatient use of oral opioids for acute and chronic noncancer pain. Many patients have left-over unused opioid pills, regardless of the indication for which they were prescribed. For example, a survey of more than 1000 US adults with recent opioid use reported that 57% had or expected to have leftover pills, and 49% planned to keep them for future use.⁵⁷

Also contributory is the over-prescription of oral take-home opioids after surgery, a problem reviewed previously in this journal,⁵⁸ and repeatedly documented further thereafter.^{46,49,51,59–65} Surgeons prescribe approximately 10% of all opioids (and another 6% by dentists), and while this pales in comparison to the 33% prescribed by family practitioners and internists, surgical prescribing accounts for millions of patients and tens of millions of unused pills left over each year.⁶⁶ For example, among nearly 2400 patients and 12 surgical procedures, a median of 30 postsurgical take-home opioid pills was prescribed per patient, and 19 pills were left-over unused.⁴⁶ A recent large meta-analysis of 44 studies involving 13,068 patients found that an average 61% (95% CI, 56–67%) of postoperative opioids were leftover, equivalent to 582,000 5mg hydrocodone tablets prescribed, and 355,000 tablets leftover, or 27 tablets leftover per person.⁶⁴

Most patients do not return or dispose of unused prescription opioids, and do not store them in locked or inaccessible locations.^{48,57,61,62,67–69} Leftover opioids may be used to self-medicate for indications other than that for which they were prescribed, voluntarily diverted to others for pain relief or other use, illegally diverted by theft, or accidentally ingested by toddlers, with consequent risks of misuse, abuse, addiction, and overdose.

Children and adolescents comprise a vulnerable population affected by the size and availability of the opioid pool.⁷⁰ Adolescent opioid misuse may lead to dependence, opioid use disorders, heroin use, and overdose.^{70,71} In 2019, approximately 670 adolescents (12-17 yr) and 1100 young adults (18-25 yr) (compared with 2625 adults 26 yr and older) initiated prescription opioid misuse *each day*.³⁶ Opioid-related pediatric hospitalizations doubled from 2004 to 2015.⁷² One-third were <6 years old, suggesting accidental ingestion, and two-thirds were 12-17 yr, suggesting deliberate misuse.⁷² Adolescents freely divert prescription opioids.⁷⁰ The source of prescription opioids misused by adolescents (12-17 yr) differs from the population as a whole, and diversion is even more important than in adults. Misused opioids are obtained by diversion (from a friend or relative for free, purchase or theft) more

by adolescents (58%) than adults (51%) and less from prescription by adolescents (28%) than adults (37%).^{36,70} Opioids are found in more than one-third of adolescents' homes, and many parents and caregivers are unaware of the risk they pose.⁷³ It is clear that current efforts to decrease adult opioid use have not diminished opioid exposure to children.^{65,72,74}

The combination of outpatient opioid overprescribing, large amounts of unused opioids, retention for future use, and storage in unsecured accessible locations, creates a vast risk space of hundreds of millions of opioid pills,⁷⁵ and opportunity for potential harm. This constitutes the opioid pool.

Managing the Size of the Opioid Pool

There are three general approaches to managing the size of the opioid pool. These are supply-side, demand-side, and disposal (Figure 2).

Supply-side opioid management

Supply-side regulation targeting restricted prescribing has been the overwhelmingly predominant focus of efforts to combat the opioid crisis. U.S. opioid prescribing is influenced by myriad laws, regulations, policies and guidelines, from numerous federal government agencies (e.g. Centers for Disease Control, Veterans Affairs Healthcare System, Department of Defense, Centers for Medicare and Medicaid Services), state and local governments (all 50 states have some form of opioid prescribing guidelines or restrictions, as do some cities), state medical boards, professional societies, health insurers, pharmacy benefit managers, pharmacies, and local hospitals and health care systems.⁴⁴ Broad policies and targeted interventions to reduce opioid prescribing include improved medical student curricula; compulsory provider education; electronic medical record systems defaults, warnings, and limits; prescription drug monitoring programs; naloxone access laws; pain clinic laws, and stringent numerical restrictions on opioid prescribing.^{28,76}

There are clear pitfalls of bowing to pressures that would result in seemingly attractive and expedient but ill-advised “one-size fits all” solutions. Many of these are outlined in the National Academies of Sciences, Engineering, and Medicine report “Pain management for people with serious illness in the context of the opioid use disorder epidemic.”⁷⁷ Overall, the nation’s response to the oral opioid crisis has been to tighten patient supplies and impose institutional and practitioner quality indicators based on pill counts. Governments, payers and pharmacies have assumed authority for limiting opioid prescribing, often in indiscriminate ways, based on misinterpretation of Centers for Disease Control guidelines or based on no real guidance at all.⁷⁸ Pill counts have become *de facto* standards employed by health care organizations to highlight their success in reducing opioid use, yet there is no discussion of how those reductions are affecting patient outcomes.⁷⁷ One crucial problem is that agencies mandating policy restrictions do not measure, nor are they accountable for, patient outcomes.⁷⁷ Mandated opioid prescribing limits may be too low to adequately control pain, or too high to reduce oversupply.⁷⁹

Another crucial problem is that supply side restrictions focus on intermediate outcomes, while ignoring patient-centric and population health outcomes. Intermediate outcomes

include prescription pill counts, amounts of opioid used, number of unused pills left-over, refill requests, opioid misuse, opioid diversion, health costs, and patterns of health care utilization (Figure 3). Patient-centric outcomes, arguably more important, include pain, adverse effects, function, recovery from illness, return to work or school, quality of life, morbidity, and mortality, and their implications for population health. Intermediate outcome statistics can also be misleading. For example, opioid prescriptions to opioid-naïve patients declined by 54% from 2012 to 2017,²⁹ and mean amounts (mg) prescribed per person decreased 13% from 2006 to 2017,⁸⁰ but average prescription duration and the number of prescriptions for >30 days both increased 38%.⁸⁰

One example of opioid prescribing guidelines hyper-focused on supply-side restriction and their consequence is cancer, where pill count policies may adversely affect patient care. Opioid prescribing guidelines intended for non-cancer populations are being inappropriately applied to cancer patients and cancer survivors, with concern about reduced access to effective pain management.⁸¹ A recent survey of cancer patients and survivors found that one-third were refused opioids by their physician, and one half were told that their pain treatment was limited by laws, guidelines, or insurance coverage.⁸¹ The expressed fear was that while concerns about opioid misuse were certainly warranted, appropriate pain management was equally as critical.

Another focus of guidelines is on postoperative opioid prescribing, where calls for guidelines have been met with a plethora of recommendations by professional societies and healthcare institutions. Yet these are highly disparate (not surprising, given the above-described variability in interpatient pain experiences and analgesic responses). Among just one surgical type (abdominopelvic surgery), a recent review identified 15 clinical practice guidelines and 26 other pertinent documents, containing 98 recommendations for discharge opioid prescribing, and there was substantial variability between them in the amount of recommended discharge opioid – even for the same procedure.⁸² Moreover, in addition to the heterogeneity of the recommendations, only a tiny fraction (11%) of recommended interventions were supported by an assessment of strength or level of evidence.⁸² And beyond surgery more broadly, there is prescribing variability within many other specific indications, by geographic region, provider type, provider, hospital, and within and between patient populations.⁴⁴

Despite well-established interpatient variability in pain and recovery trajectories, several studies have attempted to identify the one right number of opioid pills needed by all patients postoperatively, with the goal of identifying the one right amount to prescribe.^{83–85} Less stringent individualized approaches, such as those based on pre-discharge in-hospital opioid use, may be more successful,^{84,86} but they are only applicable to hospital inpatients, and not more broadly to ambulatory surgery and emergency department visits. Numerous publications have rightly recognized the need to reduce excessive post-surgical opioid prescribing and promoted various approaches. Recent examples of local success in reducing post-surgical opioid pills counts are very promising.^{87–90} However patient effects beyond this intermediate outcome are yet unknown. Enhanced recovery after surgery (ERAS) protocols that promote opioid-sparing if not opioid-free anesthesia have become widely implemented.⁹¹ Nevertheless, such protocols did not affect discharge opioid prescribing.⁹²

Some reductions in opioid amounts prescribed at discharge after surgery have even been associated with worse postoperative pain control.⁸⁵ Risks of inadequate pain control include increased morbidity, care costs, progression to chronic pain, and opioid use, delayed recovery, physical and emotional distress, and impaired physical functioning, daily activities, sleep, and return to work or school.⁴⁴

Protocols that aim to “right size” opioid prescribing in order to narrow the gap between opioid prescribing and amount used and thus reduce “leftovers” to decrease the storage and disposal burden on patients, are highly laudable, yet challenged by the problem of variability. Such protocols can represent trade-offs between opioid prescribing, use, and inadequate pain relief, as limiting discharge prescriptions to the amounts sufficient for the majority of patients means that some will have inadequate pain control.^{44,93} At present, one size fits all opioid prescribing epitomizes the dynamic tension between protocolized and individualized medicine.⁹⁴

In addition, the opioid supply chain now has two parts – that which the healthcare system controls, and a larger portion used for abuse that is illicit at its source. Decades ago this situation was the reverse, with most abused opioids originating in our medical supply. Restricting access with ill-considered policies may take pills from people who need them while leaving intact the main supply lines of the opioid crisis – primarily illicit fentanyl.

It is now recognized that supply-side approaches alone are not succeeding. Broad prescribing restrictions may be suboptimally effective because nearly half of all opioid doses and one quarter of all opioid prescriptions are accounted for by only 1% of providers.⁷⁶ In contrast, among the remaining 99% of providers, more than 85% of prescriptions were for less than the Centers for Disease Control recommendation of 50 mg morphine equivalents per day.⁷⁶ Since only a tiny fraction of providers account disproportionately for overprescribing, while most prescriptions written by the majority appear more appropriate, further broad increases in prescribing restrictions and more rigid dosing thresholds are considered unlikely to be beneficial, and more likely to reduce appropriate than inappropriate opioid use.⁷⁶

In the realm of acute pain, restrictive opioid prescribing limits have not substantially reduced actual opioid prescribing, nor have they been the primary driver for the overall downward trend in opioid prescribing in the US that has occurred over the last decade.⁹⁵ Greater restrictions on opioid prescribing are thought unlikely to be effective – and certainly not without the risk of inadequate pain treatment.⁹⁵ Moreover, sudden and/or involuntary discontinuation of chronic opioid therapy for pain due to clinician decision or supply restriction is not without potential consequence, such as withdrawal, increased or uncontrolled pain, psychological distress, increased risk of suicidal ideation, opioid-related adverse events, and overdose death (particularly illicit opioids) - the very things we are trying to prevent.^{85,96-100}

Legislative, regulatory and insurer limitations on opioid prescribing alone have not met their intended goals, and are considered unlikely to achieve them. One reason is that they impose tight restrictions on an extremely heterogeneous patient population.^{77,79} Moreover,

they focus more on intermediate outcomes, which are easily quantifiable but less important than the health outcomes that are more important to patients and population health (Figure 3).^{44,101} Since the publication of the Centers for Disease Control guidelines with strict thresholds for opioid prescribing, enthusiasm has waned for such supply-side management in some quarters. The American Medical Association, in its essay “8 keys to end the nation’s drug-overdose epidemic”, suggests eliminating ineffective opioid prescribing restrictions and shifting focus to the illicit opioid overdose epidemic.¹⁰² Even the authors of the Centers for Disease Control opioid prescribing guidelines have expressed dismay at the misapplication of their guidance.¹⁰³ While supply-side opioid policy has stayed or reduced prescription opioid misuse and associated overdose deaths, it appears to have had the unintended consequence of motivating opioid users to switch to illicit drugs and the associated consequence of increased overdose and death (Figure 1).^{28,104}

It is clear that patients could benefit from better informed practices and education regarding pain, oral opioid prescribing, and oral opioid use, and from a reduction in excessive overall and post-hospital opioid prescribing. However supply-side restriction alone is confounded by the problem of variability, and appears neither fully effective nor optimal, and further restrictions risk greater patient pain.

Demand-side opioid management

Demand-side (patient need) reduction in the opioid pool offers a more promising path forward if properly executed. That is, reducing pain and the need for opioids.¹⁰⁴ From the perspective of acute postoperative pain, the majority of patients (80%) report that their pain was not adequately managed.^{45,105–107} Acute surgical pain not only causes suffering, diminished patient satisfaction,^{108,109} but is also associated with postoperative surgical complications (i.e. surgical site and urinary tract infections),^{42,110,111} and even engenders regret for having had surgery.¹⁰⁹ The problem of chronic postoperative pain affects up to 80% of patients,^{112–114} and may lead to persistent postoperative opioid use.^{101,115–117} Postoperatively “one-third of adults receiving long-term opioid therapy report that their first opioid prescription came from a surgeon, indicating that postsurgical prescribing is important...in the opioid epidemic”,¹¹⁸ and this is cited to suggest that opioids *per se* are the sole culprit. However, this ignores the fact that all chronic postoperative pain started as acute postoperative pain, and acute postoperative pain was the reason for these one-third of patients to be prescribed opioids in the first place. It is well-established that in opioid-naïve patients, acute postoperative pain is the greatest risk factor for chronic postsurgical pain.¹¹⁹ Moreover, chronic pain is not limited to surgical patients. The incidence of new chronic pain in 1840 1-year survivors of critical illness (requiring ICU care) was 18%,¹²⁰ and a systematic review of 9 studies including 1755 patients reported a 28-77% incidence of persistent pain after intensive care.¹²¹ Neither found any difference between medical vs surgical patients in the incidence of persistent pain.

The target of greatest potential influence on the need for postoperative opioids is reducing acute perioperative pain, and the potential consequence of transition to chronic postoperative pain.^{114,119,122,123} As summarized recently, current therapeutic modalities such as multimodal analgesia, epidural analgesia, peripheral nerve blocks, perioperative

gabapentinoids, intravenous ketamine, and intravenous lidocaine, while often effective in the immediate perioperative period, do not prevent chronic postoperative pain and/or persistent postoperative opioid use.^{123–127} While pharmacologic innovations await, care model innovations may hold promise, such as the transitional pain service to provide continuity of pain care, education, and management to complicated patients after hospital discharge.^{128,129 130,131} It is imperative to find more successful methods and practices than currently available, and this unmet need should be a pressing research focus.^{94,101,123,132}

In the immediate, anesthesiologists should focus on carefully tailoring perioperative therapeutic regimens to the needs and circumstances of individual patients, and with the longest lasting benefit, preferably beyond just the immediate perioperative period and their time in hospital. If the prescribing of postoperative oral take-home opioids is to be right-sized, patients must feel confident that they will receive an adequate take-home supply to treat their pain, must receive the amount prescribed, and surgical prescribers must feel confident that they are providing enough to assure adequate analgesia and patient satisfaction, to minimize unwanted calls by patients for more, and to minimize the amount of unused leftover opioid pills. It has been recommended that perioperative initiatives focus more on reducing pain than on just reducing opioids *per se*.⁹⁴

Pool-size opioid management

Lastly, and least illuminated or pursued, is the objective of shrinking the pool of opioids present in the community, to prevent diversion and misuse. Shrinking the opioid pool represents an unfulfilled opportunity for public health benefit at scale. The pool size depends not only on supply (inflow) but also on outflow, the latter being determined by voluntary disposal and take-back of unused and left-over opioids. The size of the opioid pool has major implications for potential misuse and averse events. For example, among US adults (>12 yr) who misused prescription pain relievers in 2019, 51% received them from a friend or relative (the pool), compared with 37% by prescription from a health care provider.³⁶

Most patients with unused opioids plan to keep them for potential future need.⁵⁹ People keep unused medications because 1) it takes effort to discard them but no effort to leave them where they are, and 2) a natural inclination is to keep something that might be useful later on, such as a drug that once served a purpose (pain relief) and might do so again, particularly if future procurement is uncertain, inconvenient or expensive.¹³³ Indeed, the most common reason for patients to retain unused opioids is to have them available should they need to treat pain in the future-theirs or that of others.^{73,134} Among U.S. adults (>12 yr) who misused prescription pain relievers in 2019, the vast majority (66%) did so to relieve physical pain.³⁷ This again highlights the importance of the problem of undertreated pain, well-recognized in adults,²⁰ and more recently in children.¹³⁵ Among adults who kept unused opioids and then shared them (one of the definitions of misuse), 73% did so to help another person manage their pain.⁵⁷ Hence a major motivation for retaining unused opioids, and a barrier to shrinking the opioid pool, is patients' fear of pain and of their inability to receive proper future treatment. Another major reason patients retain unused opioids are the barriers to disposing or returning them.

Compared with the unremitting focus on restricting opioid prescribing, opioid disposal and return (take-back) have received scant attention. Patient storage of unused medications, lack of return, and lack of education by health care providers about disposal, have remained unchanged for more than a decade, even in the face of the opioid crisis.¹³⁶ Patient education about opioid disposal has been called staggeringly low.¹³⁴

Prescription Opioid Ecosystem

A new paradigm and new messages are needed. One suggestion is the concept of the Prescription Opioid Ecosystem (Figure 2). The ecosystem consists of providers/prescribers, pharmacies, patients, and disposal (and manufacturers, distributors, and pharmacy benefit managers, albeit not discussed here), all of which bear directly on the opioid pool.

The Prescription Opioid Ecosystem is a superset of the recently introduced concept of Opioid Stewardship.¹³⁷ Opioid stewardship is modeled on now-standard institutional antibiotic stewardship programs. One definition of opioid stewardship is “coordinated interventions designed to improve, monitor, and evaluate the use of opioids in order to support and protect human health”.¹³⁸ The opioid stewardship concept has also been echoed by the National Quality Forum.¹³⁹ Nevertheless, this important yet still-developing concept lacks consensus definition and implementation, and is sometimes conflated with institutional administrative superstructures or with clinical pain management approaches.^{140–143} In addition, opioid stewardship programs are institution-based and institution-specific, often focused mainly on prescribing practices, prescribing monitoring, and addiction.^{140–143} Programs are often linked to hospital pharmacy consult services or to clinical pharmacy specialists within hospitals and health systems. Lastly, they are not widely found, and variably effective.^{140–143} Programs focus on clinicians, administrators, quality assessment personnel, clinical disciplines, administrative structure, organizational policies, tasks, tracking, and reporting.^{137,141,144} These are all extremely valuable institutional efforts, but they are not patient-centric, and do not directly address patients and communities at large or the problem of the opioid pool and its consequences. The Prescription Opioid Ecosystem can include institution-based opioid stewardship, but extends well beyond, to the broader concept of opioid use, storage, return, and harm reduction, with a specific focus on patients and communities.

Prescription Opioid Ecosystem patient messaging and implementation should be patient-centric, stress safe handling and storage of opioids, opioid use only by the recipient and only for the prescribed indication, patient transition to non-opioid analgesics as recovery progresses, and then appropriate opioid return or disposal to minimize diversion, misuse and harm. One suggestion is the novel messaging that opioids are not “given” to patients (denoting permanent possession), but rather “loaned” for appropriate and recipient use only, and that they should be returned when no longer needed. The healthcare system needs to make “the right to return” as easy or easier than “the right to receive”. Inherent in this strategy, however, it is crucial that patients need to be confident and assured that their next episode of pain will be appropriately treated, lest they hoard unused opioids for fear that any such future pain and suffering will not be treated.

Opioid ecosystem education should target greater patient (and caregivers of children) engagement in pain management and safe opioid use.¹⁴⁵ Patient education by providers and other caregivers is unquestionably needed and an attractive opportunity for shrinking the opioid pool. However surveys of US adults found that 40-50% said they received no information on either safe storage or proper disposal.^{57,146} Another survey of children's caregivers found that education on proper storage was reported by only 60%, and education on disposal by 50%.⁶⁵ And opioid disposal rates are typically less than half the rate of patient education.

Opioid education is laudatory and unassailable as an ideal. Preoperative education may reduce postoperative pain scores and opioid use,¹⁴⁷ or hasten opioid cessation.¹⁴⁸ Nevertheless, it must be recognized that patient education alone is insufficient and inconsistent, effective strategies are lacking, little progress has been made, and education will require substantial effort, take considerable time, and need greater evidence of effectiveness.¹⁴⁹ Passive education (informational pages and brochures) has unfortunately not been successful. A single page document given to patients after dental surgery increased the proportion of patients who disposed or reported intent to dispose of unused opioids by only 22%.⁶⁷ Dissemination of an educational brochure about safe disposal of unused opioids doubled the disposal rate, but still only a small fraction (22%) of patients did so.¹⁵⁰ More recently, even with greater awareness of the opioid crisis, patient education handouts did not increase opioid disposal.^{151,152} Although education of children's caregivers on proper storage and disposal was reported by 60% and 50%, respectively, locked storage and disposal were reported by only 18% and 25%.⁶⁵ Moreover, there is insufficient knowledge among those providers who would need to be the educators. In an opioid knowledge assessment exam taken by physicians, nurses, and pharmacists involved in opioid administration in Pennsylvania hospitals, only 9% of respondents correctly answered all of the eleven basic questions.¹⁵³

Appropriate, rational, and safe opioid prescribing as well as safe return or disposal needs to be part of undergraduate and graduate medical and pharmacy curricula, and continuing medical and pharmacy education. Educating patients cannot occur until we educate the educators. From the perspective of postsurgical opioids, preoperative clinics, or possibly transitional pain services, typically run by anesthesiologists, could be the most opportune place for perioperative practitioner and surgical patient education about postoperative pain, opioids and other pain drugs, opioid stewardship, and opioid return/disposal. More broadly, primary care providers, who are the largest group of opioid prescribers,⁶⁶ constitute the greatest need and opportunity for provider, and in turn patient education.

Other approaches to the prescription opioid ecosystem are also needed, and which target disposal and return more specifically. Home disposal is one option. Unfortunately, home disposal guidelines for patients vary widely, can be confusing, are infrequently communicated, and are not intuitively found by patients. Contrasting recommendations, even within and between U.S. federal and state agencies (Drug Enforcement Administration, Environmental Protection Agency, state boards of pharmacy, individual state agencies) can be confusing to patients.¹⁵⁴ The U.S. FDA recommends flushing some drugs down the sink or toilet, while recommending that others should be mixed with used coffee grounds, dirt, or

cat litter, placed in a closed unmarked container, and thrown in the garbage.¹⁵⁵ In contrast, the U.S. Environmental Protection Agency advises against flushing unwanted drugs down the toilet. U.S. news media articles rarely cover flushing as an option, and often present it as environmentally harmful,¹⁵⁴. Some state guidelines contradict federal guidelines.^{156,157} In contrast to the U.S., Health Canada recommends that unused drugs be returned to local pharmacies or municipal waste disposal centers and discourages other forms of disposal (flushing, pouring down the drain or throwing in the trash).¹⁵⁸

The current difficulty of returning prescription opioids contrasts markedly with the ease of obtaining them. This is illogical and unsafe. A less confusing, more effective, and more environmentally sound approach is needed, specifically the creation and facilitation of effortless and free pathways for disposal and return, that are widely known, widely available, and widely used. Events such as National Prescription Drug Take Back Day are welcome, but occur only once per year, and in a limited 4 hour window,¹⁵⁹ and are not widely publicized and well-known.¹⁶⁰ These do collect tons of unused medications, but only a tiny fraction are opioids,¹⁶¹ and take-back events and drug disposal sites remove only a miniscule fraction (0.3%) of opioids dispensed.¹⁶² This is inadequate. More promising are year-round drug disposal locations, yet the availability, awareness and use of these sites, particularly for opioids, is insufficient.¹⁶³ Most patients (84%) surveyed would be more likely to use a take-back kiosk if it was in a frequently visited location.¹³⁴ Even though there is considerable variability in opioid prescribing, the variability in opioid consumption and thus the variability in amounts left-over are even greater.⁴⁶ Hence intervention on the disposal side may have even better impact than just trying to throttle opioid dispensing.

There needs to be common sense, convenient, widely available, accessible, appealing, and inexpensive (preferably free) methods for patients to return unused opioids. Even terminology may be influential. Return, take-back and give-back may have subtle influence on behaviors, as the former two terms connote effort required on the part of patients and potential inconvenience, while the latter does not and may even sound more genial. One approach is mailable disposal bags. Providing patients with a bag containing an inactivating modality (e.g. activated charcoal, coffee grounds) for in-home opioid disposal was found in various studies to double the disposal rate compared with an educational pamphlet (57% vs 29%),¹⁵¹ increase it by 50% (33% vs 19%),⁷⁴ increase it by 20%,¹⁶⁴ or to have no effect at all.¹⁵² An interactive web-based educational program combined with a disposal kit was more effective than just a kit alone.⁷⁴ After pediatric surgery, provision of a mail-back envelope resulted in opioid return by 19% of patients, comprising 58% of the prescriptions written.¹⁶⁵ Opioid buy-back sounds even more appealing, and may also facilitate return.⁹⁰ This novel pilot program for buy-back of post-surgical opioids (nominal \$5 reimbursement with a limit of \$50) resulted in 30% participation of 934 patients, returning 3165 unused pills (median 10 per patients, 22% of pills dispensed), at a cost of \$31 per patient. In a patient survey, most (70%) reported that compensation would lead them to dispose of unused opioids.¹³⁴

Regulations require that prescription drugs must be dispensed with patient instructions for use, and there are telephone numbers for refills on every medication container label for patient convenience, refills, and obvious business reasons. Perhaps regulations are also

needed requiring that opioids be dispensed with explicit and plain instructions for proper return or disposal, and preferably with some message on the label rather than just a handout. Perhaps patient instructions, including addresses/telephone numbers of disposal stations, and a return mailing envelope for unused drugs, should be mandatory. Such an envelope should be preaddressed and postage prepaid, to maximize return rates. More than half of patients surveyed would use such a prepaid envelope for opioid return.¹³⁴ Regulations must be federal, for uniformity, lest there be a patchwork of variable state regulations. Opioid take-back is presently subject to federal, state, and board of pharmacy regulations, which may be complex if not conflicting and certainly confusing to patients.

Practicum

What can anesthesiologists and acute pain practitioners do, and ideally together in concert with surgeons, to implement these ideas about the prescription opioid ecosystem, particularly as they apply to perioperative care? Actionable opportunities include both advocacy to improve federal opioid policy and focused perioperative care.

Prescription opioid policy

More informed, thoughtful and proactive opioid policies, and better understanding of their successes and failings, are one immediate opportunity, and should be enthusiastically advocated by practitioners. Research on federal and state opioid policy has predominantly focused on state prescription drug monitoring programs, prescribing policies, federal regulations, treatment access, and pain clinic laws.¹⁶⁶ Research on effectiveness examines proximal outcomes (effect of prescription drug monitoring programs on prescribing, effect of treatment access policies on treatment utilization), but not distal outcomes (patient and population health) and unintended consequences. Increasing complexity of the policy landscape has also been identified, with heterogeneity resulting in variable effectiveness, and the need for better methodologic rigor has also been identified.¹⁶⁶ Revision of less effective and promulgation of more effective policies should be imperative, but is however likely to be slow.

There is one novel policy approach offering remarkable potential benefit. Ideally it should be immediately available to acute pain practitioners and to surgeons prescribing postdischarge opioids. It affects the supply side of the opioid ecosystem. A new federal law, which permits partial fills of oral opioid prescriptions, particularly useful for acute and postsurgical pain, represents a substantial opportunity and underused ecosystem approach for reducing the opioid pool. This law, enacted in 2016, allows partial filling of schedule II opioid prescriptions when requested either by a patient or practitioner, and partial filling of prescriptions for schedule III-V drugs was already allowed (see Text Box 1).²⁴ Partial fills affords potential benefit to patients and society, via regulatory flexibility, reduction of opioid overuse and dependence, diminished amount of unused opioids available for misuse or diversion, and reduction of healthcare expenditures, while meeting the needs of those patients with ongoing pain who require opioids.²⁴ Importantly a patient request to the pharmacy for a partial fill would not require the consent of, or notification of, the prescribing practitioner, not require additional consent, and not impose dispensing delays,

thereby mitigating burdens to pharmacies, practitioners and patients. This gives patients the choice, and is patient-centric. It is estimated that 36 million post-surgical prescriptions annually could be partially filled.²⁴ A survey found that about half of patients would likely select partial opioid fills, but concerns did exist about future availability if needed, inconvenience of returning to the pharmacy, an additional dispensing co-pay.¹³⁴ Assuming a typical postsurgical prescription of 30 pills, and that postoperative patients consume only 33% of prescribed medication (according to one study¹⁵⁰), this leaves 723,600,000 pills unused annually. If only half of the 36 million post-surgical prescriptions were partially filled, this would reduce unused leftover opioids and the annual opioid pool by 540,000,000 pills, and accrue more than \$656 million annually in cost savings from reduced dispensing, and an additional \$3 million in disposal costs.²⁴ Success of this endeavor, however, will rest primarily on prescribers, because patients may be unlikely to request a partial fill.²⁴ Success will also require seamless no-questions-asked-no-charge fills of the unfilled prescription by pharmacies. Completing partial fills will have a cost to pharmacists, but this is estimated at less than \$15.²⁴ This cost should not be borne by patients. Of note, the National Association of Chain Drug Stores has endorsed the partial fill concept.¹⁶⁷ The small cost of partial opioid fills pales in comparison to the cost savings from pills dispensed, reduced left-over opioids, shrunken opioid pool, potential for diminished opioid misuse, addiction, and diversion, and improved public health. Federal law enabled partial opioid fills in 2016. This needs prompt implementation. Partial opioid fills could be the single most effective intervention to deplete America's medicine cabinets of unused prescription opioid pills, shrink the opioid pool, improve the prescription opioid ecosystem, and prevent misuse, diversion, and death.

In addition to the above, there may be other stakeholders and influences outside the clinical milieu that influence the opioid ecosystem. For example, to what extent do protocols of the US Department of Justice and Department of Homeland Security influence providers' abilities to prescribe medically necessary amounts of opioids? The Homeland Security website focuses primarily on stopping the flow of illicit opioids and supply reduction.¹⁶⁸ While it also states that "*demand reduction is a critical element in the U.S. government's comprehensive efforts to combat opioid abuse*" nothing follows. Similarly, the White House Office of National Drug Control Policy announcement of 2021 policy priorities appropriately emphasizes opioid use disorder treatment, access and workforce issues, and illicit supply reduction.¹⁶⁹ Perhaps the opioid ecosystem concept and enhanced opioid disposal and return can be brought to the attention of Homeland Security, and the Office of National Drug Control Policy and embraced as part of the countermeasures strategy.

Opioid practice

Immediate actions include the education of patients; anesthesia and surgery colleagues and institutions (this is generally not being adequately taught in medical school, residencies, and departments), on unmet needs for appropriate treatment of postoperative pain; appropriate, rational, optimal and balanced use of opioids for postoperative pain, opioid stewardship and opioid disposal/return; and the need for anesthesiologists to devise anesthetic and postoperative regimens for optimum pain relief, optimum recovery trajectory,

and appropriate amounts of opioid prescribing and opioid use.^{94,101,132,170,171} These are summarized in Text Box 2 and Figure 4.

How can the opioid ecosystem concept, shrinking the opioid pool, and improving opioid returns, reduce opioid-related deaths, since most deaths result from illicit opioids? It is because prescription oral opioids are a gateway to the use of heroin and illicit fentanyl. The majority of US heroin users also use prescription oral opioids,³⁶ and up to 80% of heroin-dependent individuals report initiating with prescription oral opioids.^{25,172,173} Prescription opioid-dependent patients, faced with unavailability due to decreased provider prescribing and other supply-side reductions, abuse-deterrent reformulations, tamper-resistant pill dispensers, street market shortages and high street costs, simply turned to cheaper and more accessible heroin as the unintended policy consequence,^{18,33,104} Heroin became substitution therapy for prescription opioids. Fentanyl was subsequently introduced as an efficient supply-side market response to opioid demand, prescription opioid shortages, and declining heroin purity, shortages and “supply shocks”, as well as lower production cost, easier distribution, and greater profitability of fentanyl versus heroin.^{26,27} Moreover, illicit fentanyl is increasingly being sold deceptively as adulterated or fully counterfeit prescription opioid pills, such as oxycodone, or as heroin,¹⁷⁴ and also contaminates other illicit drugs such as cocaine and methamphetamine.¹⁷⁵ End-users often unknowingly consume illicit fentanyl, as neither they nor dealers know their drugs contain fentanyl, and overdose may result. Thus, user demand is for opioids, not illicit fentanyl *per se*, and the opioid supply chain just responded with fentanyl. Therefore, by reducing the size of the opioid pool, potential diversion, and misuse, the demand for prescription opioids to misuse can be slacked, as can the market substitution demand for heroin and illicit fentanyl, as well as their use and resulting overdose. While many opioid deaths have been caused by overdoses of street drugs (e.g., fentanyl), not prescription opioids, it is considered inarguable that oral prescription opioids continue to play a prominent role in the opioid crisis.¹⁷⁶

A caveat about shrinking the prescription opioid supply, particularly given the number of individuals with existing opioid use disorder, is that we not repeat past unintended consequences. Shrinking of the prescription opioid pool will need expansion of programs for medication assisted therapy of opioid use disorder.

Conclusion

The opioid epidemic has not abated. The paradox is that opioid overdoses continue to escalate while opioid prescribing has decreased, despite the innumerable research publications documenting opioid prescribing and use, and the plethora of well-intentioned federal, state, local, and institutional legislation and policies, proliferation of guidelines, efforts by practitioners, and public awareness. More than half of dispensed opioids in the US are unused, and most are not stored appropriately, creating a prescription opioid pool susceptible to diversion, misuse, and addiction. Attempts to solve the problem by restricting patient supply alone have not succeeded, and the prescription opioid pool remains large. Additional novel efforts to shrink the pool are needed, both by diminishing demand (reducing pain through better treatment) and by facilitating opioid disposal and return. The prescription opioid ecosystem model encompasses these concepts, can be readily understood

by providers and patients in a simple supply-demand paradigm, and highlights actionable policy and patient care opportunities.

Acknowledgements

We thank Dr. Michael Avram for helpful input on this article.

Supported by National Institutes of Health grant R01 DA042985 (Bethesda, MD) to Dr. Kharasch and Department of Veterans Affairs grant No. I01 BX000881 (Washington, D.C.) to Dr. Clark

References

1. Jannetto PJ: The North American opioid epidemic. *Therapeutic Drug Monitoring* 2021;43:1–5 [PubMed: 33337587]
2. The Council of Economic Advisers: The full cost of the opioid crisis: \$2.5 trillion over four years. <https://trumpwhitehouse.archives.gov/articles/full-cost-opioid-crisis-2-5-trillion-four-years/> 2019
3. Hubbard WK: Getting serious about opioid regulation. *JAMA Intern Med* 2020;180:309–310 [PubMed: 31886829]
4. The Economist: The wider effects of America's opioid epidemic. 2020 <https://www.economist.com/business/2020/01/16/the-wider-effects-of-americas-opioid-epidemic>
5. Oquendo MA, Volkow ND: Suicide: A silent contributor to opioid-overdose deaths. *N Engl J Med* 2018;378:1567–1569 [PubMed: 29694805]
6. Florence C, Luo F, Rice K: The economic burden of opioid use disorder and fatal opioid overdose in the United States, 2017. *Drug Alcohol Depend* 2021;218:108350 [PubMed: 33121867]
7. Belzak L, Halverson J: The opioid crisis in Canada: a national perspective. *Health Promot Chronic Dis Prev Can* 2018;38:224–233 [PubMed: 29911818]
8. Verhamme KMC, Bohnen AM: Are we facing an opioid crisis in Europe? *Lancet Public Health* 2019;4:e483–e484 [PubMed: 31444002]
9. Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A: Trends in use and misuse of opioids in the Netherlands: a retrospective, multi-source database study. *Lancet Public Health* 2019;4:e498–e505 [PubMed: 31444001]
10. Levy N, Lord LJ, Lobo DN: UK recommendations on opioid stewardship. *BMJ* 2021;372:m4901 [PubMed: 33402365]
11. Harbaugh CM, Gadepalli SK: Pediatric postoperative opioid prescribing and the opioid crisis. *Curr Opin Pediatr* 2019;31:378–385 [PubMed: 31090580]
12. Haley DF, Saitz R: The opioid epidemic during the COVID-19 pandemic. *JAMA* 2020;324:1615–1617 [PubMed: 32945831]
13. Centers for Disease Control Health Alert Network: Increase in fatal drug overdoses across the United States driven by synthetic opioids before and during the COVID-19 pandemic. 2020, <https://emergency.cdc.gov/han/2020/han00438.asp>,
14. American Medical Association: Issue brief: Nation's drug-related overdose and death epidemic continues to worsen. 2021 <https://www.ama-assn.org/system/files/2020-12/issue-brief-increases-in-opioid-related-overdose.pdf>
15. Norton A, Kerr T: Applying the lessons of COVID-19 response to Canada's worsening opioid epidemic. *EClinicalMedicine* 2020;29:100633 [PubMed: 33235987]
16. Linas BP, Savinkina A, Barbosa C, Mueller PP, Cerda M, Keyes K, Chhatwal J: A clash of epidemics: Impact of the COVID-19 pandemic response on opioid overdose. *J Subst Abuse Treat* 2021;120:108158 [PubMed: 33298298]
17. Stoddard KI, Huggett DB: Wastewater effluent hydrocodone concentrations as an indicator of drug disposal program success. *Bull Environ Contam Toxicol* 2015;95:139–44 [PubMed: 26067702]
18. Dasgupta N, Beletsky L, Ciccarone D: Opioid crisis: No easy fix to its social and economic determinants. *Am J Public Health* 2018;108:182–186 [PubMed: 29267060]

19. Hedegaard H, Miniño AM, Warner M: Drug overdose deaths in the United States, 1999–2018. Hyattsville, MD, National Center for Health Statistics, 2020
20. Skolnick P, Volkow ND: Re-energizing the development of pain therapeutics in light of the opioid epidemic. *Neuron* 2016;92:294–297 [PubMed: 27764663]
21. Pitcher MH, Von Korff M, Bushnell MC, Porter L: Prevalence and profile of high-impact chronic pain in the United States. *J Pain* 2019;20:146–160 [PubMed: 30096445]
22. The Council of Economic Advisers: The role of opioid prices in the evolving opioid crisis. 2019; <https://www.whitehouse.gov/wp-content/uploads/2019/04/The-Role-of-Opioid-Prices-in-the-Evolving-Opioid-Crisis.pdf>
23. Seltzer N: The economic underpinnings of the drug epidemic. *SSM Popul Health* 2020;12:100679 [PubMed: 33319025]
24. Drug Enforcement Administration: Proposed rule: Partial filling of prescriptions for schedule II controlled substances, 21 CFR Part 1306, Docket No. DEA-469. Federal Register 2020, https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr1204_2.pdf
25. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP: The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. *JAMA Psychiatry* 2014;71:821–6 [PubMed: 24871348]
26. Mars SG, Rosenblum D, Ciccarone D: Illicit fentanyl in the opioid street market: desired or imposed? *Addiction* 2019;114:774–780 [PubMed: 30512204]
27. DEA Intelligence Program: Fentanyl flow to the United States. DEA Intelligence Report DEA-DCT-DIR-008-20, 2020 <https://www.dea.gov/documents/2020/2020-03/2020-03-06/fentanyl-flow-united-states>
28. Lee B, Zhao W, Yang KC, Ahn YY, Perry BL: Systematic evaluation of state policy interventions targeting the US opioid epidemic, 2007-2018. *JAMA Netw Open* 2021;4:e2036687 [PubMed: 33576816]
29. Zhu W, Chernew ME, Sherry TB, Maestas N: Initial opioid prescriptions among U.S. commercially insured patients, 2012-2017. *N Engl J Med* 2019;380:1043–1052 [PubMed: 30865798]
30. Centers for Disease Control and Prevention: U.S. Opioid dispensing rate maps. 2020, <https://www.cdc.gov/drugoverdose/maps/rxrate-maps.html>
31. Paulozzi LJ, Mack KA, Jones CM: Vital signs: Overdoses of prescription opioid pain relievers—United States, 1999–2008. *MMWR* 2011;60:1487–92 [PubMed: 22048730]
32. Centers for Disease Control and Prevention: 2019 annual surveillance report of drug-related risks and outcomes — United States. 2019 <https://www.cdc.gov/drugoverdose/pdf/pubs/2019-cdc-drug-surveillance-report.pdf>
33. Alpert A, Powell D, Pacula RL: Supply-side drug policy in the presence of substitutes: Evidence from the introduction of abuse-deterrent opioids. *Am Econ J Econ Policy* 2018;10:1–35 [PubMed: 34326924]
34. Wilson N, Kariisa M, Seth P, Smith Ht, Davis NL: Drug and opioid-involved overdose deaths - United States, 2017-2018. *MMWR Morb Mortal Wkly Rep* 2020;69:290–297 [PubMed: 32191688]
35. Substance Abuse and Mental Health Services Administration: Key substance use and mental health indicators in the United States: Results from the 2016 National Survey on Drug Use and Health (HHS Publication No. SMA 17-5044, NSDUH Series H-52). Rockville, MD, 2017, <https://www.samhsa.gov/data/report/key-substance-use-and-mental-health-indicators-united-states-results-2016-national-survey>
36. Substance Abuse and Mental Health Services Administration: Key substance use and mental health indicators in the United States: Results from the 2019 National Survey on Drug Use and Health (HHS Publication No. PEP20-07-01-001, NSDUH Series H-55). Rockville, MD, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration., 2020, <https://www.samhsa.gov/data/report/2019-nsduh-annual-national-report>
37. Substance Abuse and Mental Health Services Administration: Key substance use and mental health indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19-5068, NSDUH Series H-54). Rockville, MD, Center for Behavioral

- Health Statistics and Quality, Substance Abuse and Mental Health Services Administration., 2019, <https://www.samhsa.gov/data/report/2018-nsduh-annual-national-report>
38. Ahmad FB, Rossen LM, Sutton P: Provisional drug overdose death counts. National Center for Health Statistics, 2021 <https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm>
 39. Mattson C, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL: Trends and geographic patterns in drug and synthetic opioid overdose deaths — United States, 2013–2019. *MMWR Morb Mortal Wkly Rep* 2021;70:202–207 [PubMed: 33571180]
 40. Jones CM, Mack KA, Paulozzi LJ: Pharmaceutical overdose deaths, United States, 2010. *JAMA* 2013;309:657–9 [PubMed: 23423407]
 41. Volkow ND, Frieden TR, Hyde PS, Cha SS: Medication-assisted therapies--tackling the opioid-overdose epidemic. *N Engl J Med* 2014;370:2063–6 [PubMed: 24758595]
 42. Hernandez-Boussard T, Graham LA, Desai K, Wahl TS, Aucoin E, Richman JS, Morris MS, Itani KM, Telford GL, Hawn MT: The fifth vital sign: postoperative pain predicts 30-day readmissions and subsequent emergency department visits. *Ann Surg* 2017;266:516–524 [PubMed: 28657940]
 43. Vasilopoulos T, Wardhan R, Rashidi P, Fillingim RB, Wallace MR, Crispen PL, Parvataneni HK, Prieto HA, Machuca TN, Hughes SJ, Murad GJA, Tighe PJ: Patient and procedural determinants of postoperative pain trajectories. *Anesthesiology* 2021;134:421–434 [PubMed: 33449996]
 44. National Academies of Sciences Engineering and Medicine: Framing opioid prescribing guidelines for acute pain: Developing the evidence. Washington, DC, The National Academies Press, 2020
 45. Meissner W, Zaslansky R: A survey of postoperative pain treatments and unmet needs. *Best Pract Res Clin Anaesthesiol* 2019;33:269–286 [PubMed: 31785713]
 46. Howard R, Fry B, Gunaseelan V, Lee J, Waljee J, Brummett C, Campbell D Jr., Seese E, Englesbe M, Vu J: Association of opioid prescribing with opioid consumption after surgery in Michigan. *JAMA Surg* 2019;154:e184234 [PubMed: 30422239]
 47. Bartels K, Mayes LM, Dingmann C, Bullard KJ, Hopfer CJ, Binswanger IA: Opioid use and storage patterns by patients after hospital discharge following surgery. *PLoS One* 2016;11:e0147972 [PubMed: 26824844]
 48. Osmundson SS, Schornack LA, Grash JL, Zuckerwise LC, Young JL, Richardson MG: Postdischarge opioid use after Cesarean delivery. *Obstet Gynecol* 2017;130:36–41 [PubMed: 28594766]
 49. Thiels CA, Anderson SS, Ubl DS, Hanson KT, Bergquist WJ, Gray RJ, Gazelka HM, Cima RR, Habermann EB: Wide variation and overprescription of opioids after elective surgery. *Ann Surg* 2017;266:564–573 [PubMed: 28697049]
 50. Horton JD, Munawar S, Corrigan C, White D, Cina RA: Inconsistent and excessive opioid prescribing after common pediatric surgical operations. *J Pediatr Surg* 2019;54:1427–1431 [PubMed: 30057208]
 51. Hill MV, McMahon ML, Stucke RS, Barth RJ Jr.: Wide variation and excessive dosage of opioid prescriptions for common general surgical procedures. *Ann Surg* 2017;265:709–14 [PubMed: 27631771]
 52. Cartmill RS, Yang DY, Walker BJ, Bradfield YS, Kille TL, Su RR, Kohler JE: Opioid prescribing to preteen children undergoing ambulatory surgery in the United States. *Surgery* 2021:in press
 53. Blay E Jr., Nooromid MJ, Bilimoria KY, Holl JL, Lambert B, Johnson JK, Stulberg JJ: Variation in post-discharge opioid prescriptions among members of a surgical team. *Am J Surg* 2018;216:25–30 [PubMed: 29129263]
 54. Santosa KB, Wang CS, Hu HM, Brummett CM, Englesbe MJ, Waljee JF: Surgeon experience and opioid prescribing. *Am J Surg* 2020:in press
 55. Eid AI, DePesa C, Nordestgaard AT, Kongkaewpaisan N, Lee JM, Kongwibulwut M, Han K, Mendoza A, Rosenthal M, Saillant N, Lee J, Fagenholz P, King D, Velmahos G, Kaafarani HMA: Variation of opioid prescribing patterns among patients undergoing similar surgery on the same acute care surgery service of the same institution: Time for standardization? *Surgery* 2018;164:926–930 [PubMed: 30049481]
 56. Kaafarani HMA, Han K, El Moheb M, Kongkaewpaisan N, Jia Z, El Hechi MW, van Wijck S, Breen K, Eid A, Rodriguez G, Kongwibulwut M, Nordestgaard AT, Sakran JV, Ezzeddine H, Joseph B, Hamidi M, Ortega C, Flores SL, Gutierrez-Sougarret BJ, Qin H, Yang J, Gao

- R, Wang Z, Gao Z, Prichayudh S, Durmaz S, van der Wilden G, Santin S, Ribeiro MAF Jr., Noppakunsomboon N, Alami R, El-Jamal L, Naamani D, Velmahos G, Lillemoe KD: Opioids after surgery in the United States versus the rest of the world: The international patterns of opioid prescribing (IPOP) multicenter study. *Ann Surg* 2020:in press
57. Kennedy-Hendricks A, Gielen A, McDonald E, McGinty EE, Shields W, Barry CL: Medication sharing, storage, and disposal practices for opioid medications among US adults. *JAMA Intern Med* 2016;176:1027–9 [PubMed: 27295629]
 58. Kharasch ED, Brunt LM: Perioperative opioids and public health. *Anesthesiology* 2016;124:960–5 [PubMed: 26808634]
 59. Khan U, Bloom RA, Nicell JA, Laurenson JP: Risks associated with the environmental release of pharmaceuticals on the U.S. Food and Drug Administration “flush list”. *Sci Total Environ* 2017;609:1023–1040 [PubMed: 28787777]
 60. Bateman BT, Cole NM, Maeda A, Burns SM, Houle TT, Huybrechts KF, Clancy CR, Hopp SB, Ecker JL, Ende H, Grewe K, Raposo Corradini B, Schoenfeld RE, Sankar K, Day LJ, Harris L, Booth JL, Flood P, Bauer ME, Tsen LC, Landau R, Leffert LR: Patterns of opioid prescription and use after Cesarean delivery. *Obstet Gynecol* 2017;130:29–35 [PubMed: 28594763]
 61. Bicket MC, Long JJ, Pronovost PJ, Alexander GC, Wu CL: Prescription opioid analgesics commonly unused after surgery: A systematic review. *JAMA Surg* 2017;152:1066–71 [PubMed: 28768328]
 62. Feinberg AE, Chesney TR, Srikandarajah S, Acuna SA, McLeod RS: Opioid use after discharge in postoperative patients: A systematic review. *Ann Surg* 2018;267:1056–1062 [PubMed: 29215370]
 63. Neuman MD, Bateman BT, Wunsch H: Inappropriate opioid prescription after surgery. *Lancet* 2019;393:1547–1557 [PubMed: 30983590]
 64. Schirle L, Stone AL, Morris MC, Osmundson SS, Walker PD, Dietrich MS, Bruehl S: Leftover opioids following adult surgical procedures: a systematic review and meta-analysis. *Syst Rev* 2020;9:139 [PubMed: 32527307]
 65. Sloss KR, Vargas G, Brummett CM, Englesbe MJ, Waljee JF, Gadepalli S, Harbaugh C: Association of caregiver-reported education with locked storage and disposal of prescription opioids after children’s surgery. *J Pediatr Surg* 2020;55:2442–2447 [PubMed: 32507640]
 66. Levy B, Paulozzi L, Mack KA, Jones CM: Trends in opioid analgesic-prescribing rates by specialty, U.S., 2007-2012. *Am J Prev Med* 2015;49:409–13 [PubMed: 25896191]
 67. Maughan BC, Hersh EV, Shofer FS, Wanner KJ, Archer E, Carrasco LR, Rhodes KV: Unused opioid analgesics and drug disposal following outpatient dental surgery: A randomized controlled trial. *Drug Alcohol Depend* 2016;168:328–334 [PubMed: 27663358]
 68. Monitto CL, Hsu A, Gao S, Vozzo PT, Park PS, Roter D, Yenokyan G, White ED, Kattail D, Edgeworth AE, Vasquez KJ, Atwater SE, Shay JE, George JA, Vickers BA, Kost-Byerly S, Lee BH, Yaster M: Opioid prescribing for the treatment of acute pain in children on hospital discharge. *Anesth Analg* 2017;125:2113–2122 [PubMed: 29189368]
 69. Thiels CA, Ubl DS, Yost KJ, Dowdy SC, Mabry TM, Gazelka HM, Cima RR, Habermann EB: Results of a prospective, multicenter initiative aimed at developing opioid-prescribing guidelines after surgery. *Ann Surg* 2018;268:457–468 [PubMed: 30004924]
 70. Kelley-Quon LI, Kirkpatrick MG, Ricca RL, Baird R, Harbaugh CM, Brady A, Garrett P, Wills H, Argo J, Diefenbach KA, Henry MCW, Sola JE, Mahdi EM, Goldin AB, St Peter SD, Downard CD, Azarow KS, Shields T, Kim E: Guidelines for opioid prescribing in children and adolescents after surgery: An expert panel opinion. *JAMA Surg* 2021;156:76–90 [PubMed: 33175130]
 71. Kelley-Quon LI, Cho J, Strong DR, Miech RA, Barrington-Trimis JL, Kechter A, Leventhal AM: Association of nonmedical prescription opioid use with subsequent heroin use initiation in adolescents. *JAMA Pediatr* 2019:e191750 [PubMed: 31282942]
 72. Kane JM, Colvin JD, Bartlett AH, Hall M: Opioid-related critical care resource use in US children’s hospitals. *Pediatrics* 2018;141:e20173335 [PubMed: 29507166]
 73. Garbutt JM, Kulka K, Dodd S, Sterkel R, Plax K: Opioids in adolescents’ homes: Prevalence, caregiver attitudes, and risk reduction opportunities. *Acad Pediatr* 2019;19:103–108 [PubMed: 29981856]

74. Voepel-Lewis T, Farley FA, Grant J, Tait AR, Boyd CJ, McCabe SE, Weber M, Harbaugh CM, Zikmund-Fisher BJ: Behavioral intervention and disposal of leftover opioids: A randomized trial. *Pediatrics* 2020;145:e20191431 [PubMed: 31871245]
75. Katz NP, Birnbaum HG, Castor A: Volume of prescription opioids used nonmedically in the United States. *J Pain Palliat Care Pharmacother* 2010;24:141–4 [PubMed: 20504136]
76. Kiang MV, Humphreys K, Cullen MR, Basu S: Opioid prescribing patterns among medical providers in the United States, 2003-17: retrospective, observational study. *BMJ* 2020;368:16968 [PubMed: 31996352]
77. National Academies of Sciences Engineering and Medicine: Pain management for people with serious illness in the context of the opioid use disorder epidemic: Proceedings of a workshop. Washington, DC, The National Academies Press, 2019
78. Kroenke K, Alford DP, Argoff C, Canlas B, Covington E, Frank JW, Haake KJ, Hanling S, Hooten WM, Kertesz SG, Kravitz RL, Krebs EE, Stanos SP, Sullivan M: Challenges with implementing the Centers for Disease Control and Prevention opioid guideline: A consensus panel report. *Pain Med* 2019;20:724–735 [PubMed: 30690556]
79. Chua KP, Brummett CM, Waljee JF: Opioid prescribing limits for acute pain: Potential problems with design and implementation. *JAMA* 2019;321:643–644 [PubMed: 30703214]
80. Schieber LZ, Guy GP Jr., Seth P, Young R, Mattson CL, Mikosz CA, Schieber RA: Trends and patterns of geographic variation in opioid prescribing practices by state, United States, 2006-2017. *JAMA Netw Open* 2019;2:e190665 [PubMed: 30874783]
81. Jairam V, Yang DX, Pasha S, Soulos PR, Gross CP, Yu JB, Park HS: Temporal trends in opioid prescribing patterns among oncologists in the medicare population. *J Natl Cancer Inst* 2020:in press
82. Zhang DDQ, Dossa F, Arora A, Cusimano MC, Speller B, Little T, Ladha K, Brar S, Urbach DR, Tricco AC, Wijesundera DN, Clarke HA, Baxter NN: Recommendations for the prescription of opioids at discharge after abdominopelvic surgery: A systematic review. *JAMA Surg* 2020:in press
83. Chiu AS, Jean RA, Hoag JR, Freedman-Weiss M, Healy JM, Pei KY: Association of lowering default pill counts in electronic medical record systems with postoperative opioid prescribing. *JAMA Surg* 2018;153:1012–1019 [PubMed: 30027289]
84. Hill MV, Stucke RS, Billmeier SE, Kelly JL, Barth RJ Jr.: Guideline for discharge opioid prescriptions after inpatient general surgical procedures. *J Am Coll Surg* 2018;226:996–1003 [PubMed: 29198638]
85. Zhang DDQ, Sussman J, Dossa F, Jivraj N, Ladha K, Brar S, Urbach D, Tricco AC, Wijesundera DN, Clarke HA, Baxter NN: A systematic review of behavioral interventions to decrease opioid prescribing after surgery. *Ann Surg* 2020;271:266–278 [PubMed: 31356268]
86. Osmundson SS, Raymond BL, Kook BT, Lam L, Thompson EB, Schornack LA, Voorhees CE, Richardson MG: Individualized compared with standard postdischarge oxycodone prescribing after cesarean birth: A randomized controlled trial. *Obstet Gynecol* 2018;132:624–630 [PubMed: 30095773]
87. Howard R, Waljee J, Brummett C, Englesbe M, Lee J: Reduction in opioid prescribing through evidence-based prescribing guidelines. *JAMA Surg* 2018;153:285–287 [PubMed: 29214318]
88. Vu JV, Howard RA, Gunaseelan V, Brummett CM, Waljee JF, Englesbe MJ: Statewide implementation of postoperative opioid prescribing guidelines. *N Engl J Med* 2019;381:680–682 [PubMed: 31412184]
89. Findlay BL, Britton CJ, Glasgow AE, Gettman MT, Tyson MD, Pak RW, Viers BR, Habermann EB, Ziegelmann MJ: Long-term success with diminished opioid prescribing after implementation of standardized postoperative opioid prescribing guidelines: An interrupted time series analysis. *Mayo Clin Proc* 2021;96:1135–1146 [PubMed: 33958051]
90. Liu JY, Anderson JC, Franklin JS, Gesek FA, Soybel DI: Nudging patients and surgeons to change ambulatory surgery pain management: Results from an opioid buyback program. *Surgery* 2021:in press
91. Shanthanna H, Ladha KS, Kehlet H, Joshi GP: Perioperative opioid administration: A critical review of opioid-free versus opioid-sparing approaches. *Anesthesiology* 2021;134:645–659 [PubMed: 32991672]

92. Brandal D, Keller MS, Lee C, Grogan T, Fujimoto Y, Gricourt Y, Yamada T, Rahman S, Hofer I, Kazanjian K, Sack J, Mahajan A, Lin A, Cannesson M: Impact of enhanced recovery after surgery and opioid-free anesthesia on opioid prescriptions at discharge from the hospital: A historical-prospective study. *Anesth Analg* 2017;125:1784–1792 [PubMed: 29049123]
93. Mosher HJ: Nudging our way to opioid ‘right-sizing’. *Jt Comm J Qual Patient Saf* 2019;45:414–415 [PubMed: 31103476]
94. Kharasch ED, Clark JD: Opioid-free anesthesia: Time to regain our balance. *Anesthesiology* 2021;134:509–14 [PubMed: 33630018]
95. Chua KP, Kimmel L, Brummett CM: Disappointing early results from opioid prescribing limits for acute pain. *JAMA Surg* 2020;155:375–6 [PubMed: 32159750]
96. Demidenko MI, Dobscha SK, Morasco BJ, Meath THA, Ilgen MA, Lovejoy TI: Suicidal ideation and suicidal self-directed violence following clinician-initiated prescription opioid discontinuation among long-term opioid users. *Gen Hosp Psychiatry* 2017;47:29–35 [PubMed: 28807135]
97. James JR, Scott JM, Klein JW, Jackson S, McKinney C, Novack M, Chew L, Merrill JO: Mortality after discontinuation of primary care-based chronic opioid therapy for pain: A retrospective cohort study. *J Gen Intern Med* 2019;34:2749–2755 [PubMed: 31468341]
98. Mark TL, Parish W: Opioid medication discontinuation and risk of adverse opioid-related health care events. *J Subst Abuse Treat* 2019;103:58–63 [PubMed: 31079950]
99. US Food and Drug Administration: FDA identifies harm reported from sudden discontinuation of opioid pain medicines and requires label changes to guide prescribers on gradual, individualized tapering. FDA Drug Safety Communication. 2019 <https://www.fda.gov/drugs/drug-safety-and-availability/fda-identifies-harm-reported-sudden-discontinuation-opioid-pain-medicines-and-requires-label-changes>
100. Hallvik SE, El Ibrahim S, Johnston K, Geddes J, Leichtling G, Korhuis PT, Hartung DM: Patient outcomes following opioid dose reduction among patients with chronic opioid therapy. *Pain* 2021: in press
101. Kharasch ED, Clark JD: Persistent postoperative opioid use: Perception, progress, and promise. *Anesthesiology* 2020;132:1304–1306 [PubMed: 32243331]
102. Smith TM: 8 keys to end the nation’s drug-overdose epidemic. 2021 <https://www.ama-assn.org/delivering-care/opioids/8-keys-end-nation-s-drug-overdose-epidemic>
103. Dowell D, Haegerich T, Chou R: No shortcuts to safer opioid prescribing. *N Engl J Med* 2019;380:2285–2287 [PubMed: 31018066]
104. Cicero TJ: Is a reduction in access to prescription opioids the cure for the current opioid crisis? *Am J Public Health* 2018;108:1322–1323 [PubMed: 30207773]
105. Gan TJ: Poorly controlled postoperative pain: prevalence, consequences, and prevention. *J Pain Res* 2017;10:2287–2298 [PubMed: 29026331]
106. Borys M, Zyzak K, Hanych A, Domagala M, Galkin P, Galaszkiwicz K, Klapat A, Wroblewski K, Miekina J, Onichimowski D, Czuczwar M: Survey of postoperative pain control in different types of hospitals: a multicenter observational study. *BMC Anesthesiol* 2018;18:83 [PubMed: 30021520]
107. Joshi GP, Kehlet H: Postoperative pain management in the era of ERAS: An overview. *Best Pract Res Clin Anaesthesiol* 2019;33:259–267 [PubMed: 31785712]
108. Gupta A, Daigle S, Mojica J, Hurley RW: Patient perception of pain care in hospitals in the United States. *J Pain Res* 2009;2:157–64 [PubMed: 21197302]
109. Berkowitz R, Vu J, Brummett C, Waljee J, Englesbe M, Howard R: The impact of complications and pain on patient satisfaction. *Ann Surg* 2021;273:1127–1134 [PubMed: 31663968]
110. van Boekel RLM, Warle MC, Nielen RGC, Vissers KCP, van der Sande R, Bronkhorst EM, Lerou JGC, Steegers MAH: Relationship between postoperative pain and overall 30-day complications in a broad surgical population: An observational study. *Ann Surg* 2019;269:856–865 [PubMed: 29135493]
111. Albers KI, van Helden EV, Dahan A, Martini CH, Bruintjes MHD, Scheffer GJ, Steegers MAH, Keijzer C, Warle MC: Early postoperative pain after laparoscopic donor nephrectomy predicts 30-day postoperative infectious complications: a pooled analysis of randomized controlled trials. *Pain* 2020;161:1565–1570 [PubMed: 32107359]

112. Perkins FM, Kehlet H: Chronic pain as an outcome of surgery. A review of predictive factors. *Anesthesiology* 2000;93:1123–1133 [PubMed: 11020770]
113. Richebé P, Capdevila X, Rivat C: Persistent postsurgical pain: Pathophysiology and preventative pharmacologic considerations. *Anesthesiology* 2018;129:590–607 [PubMed: 29738328]
114. Glare P, Aubrey KR, Myles PS: Transition from acute to chronic pain after surgery. *Lancet* 2019;393:1537–1546 [PubMed: 30983589]
115. Larach DB, Sahara MJ, As-Sanie S, Moser SE, Urquhart AG, Lin J, Hassett AL, Wakeford JA, Clauw DJ, Waljee JF, Brummett CM: Response to the Comment on “Patient Factors Associated With Opioid Consumption in the Month Following Major Surgery” *Ann Surg* 2021; 274: e199–e200 [PubMed: 31804394]
116. Pagé MG, Kudrina I, Zomahoun HTV, Croteau J, Ziegler D, Ngangue P, Martin E, Fortier M, Boisvert EE, Beaulieu P, Charbonneau C, Cogan J, Daoust R, Martel MO, Neron A, Richebe P, Clarke H: A systematic review of the relative frequency and risk factors for prolonged opioid prescription following surgery and trauma among adults. *Ann Surg* 2020;271:845–854 [PubMed: 31188226]
117. Jivraj NK, Raghavji F, Bethell J, Wijesundera DN, Ladha K, Bateman BT, Neuman M, Wunsch H: Persistent postoperative opioid use: a systematic review of definitions and population based cohort study. *Anesthesiology* 2020;132:1528–1539 [PubMed: 32243330]
118. Wetzel M, Hockenberry J, Raval MV: Interventions for postsurgical opioid prescribing: a systematic review. *JAMA Surg* 2018;153:948–954 [PubMed: 30140931]
119. Katz J, Seltzer Z: Transition from acute to chronic postsurgical pain: risk factors and protective factors. *Expert Rev Neurother* 2009;9:723–44 [PubMed: 19402781]
120. Koster-Brouwer ME, Rijdsdijk M, van Os WKM, Soliman IW, Slooter AJC, de Lange DW, van Dijk D, Bonten MJM, Cremer OL: Occurrence and risk factors of chronic pain after critical illness. *Crit Care Med* 2020;48:680–687 [PubMed: 32039992]
121. Mäkinen OJ, Bäcklund ME, Liisanantti J, Peltomaa M, Karlsson S, Kalliomäki M-L: Persistent pain in intensive care survivors: a systematic review. *Br J Anaesth* 2020;125:149–158 [PubMed: 32564888]
122. Pozek JP, Beausang D, Baratta JL, Viscusi ER: The acute to chronic pain transition: Can chronic pain be prevented? *Med Clin North Am* 2016;100:17–30 [PubMed: 26614716]
123. Carley ME, Chaparro LE, Choinière M, Kehlet H, Moore RA, VanDenKerkhof E, Gilron I: Pharmacotherapy for the prevention of chronic pain after surgery in adults: An updated systematic review and meta-analyses. *Anesthesiology* 2021;135:304–25 [PubMed: 34237128]
124. Ladha KS, Paterno E, Liu J, Bateman BT: Impact of perioperative epidural placement on postdischarge opioid use in patients undergoing abdominal surgery. *Anesthesiology* 2016;124:396–403 [PubMed: 26575145]
125. Mueller KG, Memtsoudis SG, Mariano ER, Baker LC, Mackey S, Sun EC: Lack of association between the use of nerve blockade and the risk of persistent opioid use among patients undergoing shoulder arthroplasty: Evidence from the marketscan database. *Anesth Analg* 2017;125:1014–1020 [PubMed: 28742777]
126. Sun EC, Bateman BT, Memtsoudis SG, Neuman MD, Mariano ER, Baker LC: Lack of association between the use of nerve blockade and the risk of postoperative chronic opioid use among patients undergoing total knee arthroplasty: Evidence from the Marketscan database. *Anesth Analg* 2017;125:999–1007 [PubMed: 28430692]
127. Verret M, Lauzier F, Zarychanski R, Perron C, Savard X, Pinard A-M, Leblanc G, Cossi M-J, Neveu X, Turgeon AF: Perioperative use of gabapentinoids for the management of postoperative acute pain: A systematic review and meta-analysis. *Anesthesiology* 2020;133:265–279 [PubMed: 32667154]
128. Katz J, Weinrib A, Fashler SR, Katznelzon R, Shah BR, Ladak SS, Jiang J, Li Q, McMillan K, Santa Mina D, Wentlandt K, McRae K, Tamir D, Lyn S, de Perrot M, Rao V, Grant D, Roche-Nagle G, Cleary SP, Hofer SO, Gilbert R, Wijesundera D, Ritvo P, Janmohamed T, O’Leary G, Clarke H: The Toronto General Hospital Transitional Pain Service: Development and implementation of a multidisciplinary program to prevent chronic postsurgical pain. *J Pain Res* 2015;8:695–702 [PubMed: 26508886]

129. Clarke H, Azargive S, Montbriand J, Nicholls J, Sutherland A, Valeeva L, Boulis S, McMillan K, Ladak SSSJ, Ladha K, Katznelson R, McRae K, Tamir D, Lyn S, Huang A, Weinrib A, Katz J: Opioid weaning and pain management in postsurgical patients at the Toronto General Hospital Transitional Pain Service. *Can J Pain* 2018;2:236–247 [PubMed: 35005382]
130. Mikhaeil J, Ayoo K, Clarke H, W sowicz M, Huang A: Review of the Transitional Pain Service as a method of postoperative opioid weaning and a service aimed at minimizing the risk of chronic post-surgical pain. *Anaesthesiol Intensive Ther* 2020;52:148–153 [PubMed: 32702941]
131. Sun EC, Mariano ER, Narouze S, Gabriel RA, Elsharkawy H, Gulur P, Merrick SK, Harrison TK, Clark JD: Making a business plan for starting a transitional pain service within the US healthcare system. *Reg Anesth Pain Med* 2021;46:727–31 [PubMed: 33879540]
132. Kharasch ED, Avram MJ, Clark JD: Rational perioperative opioid management in the era of the opioid crisis. *Anesthesiology* 2020;132:603–605 [PubMed: 32058348]
133. Wu PE, Juurlink DN: Unused prescription drugs should not be treated like leftovers. *CMAJ* 2014;186:815–6 [PubMed: 24799553]
134. Buffington DE, Lozicki A, Alfieri T, Bond TC: Understanding factors that contribute to the disposal of unused opioid medication. *J Pain Res* 2019;12:725–732 [PubMed: 30863145]
135. Eccleston C, Fisher E, Howard RF, Slater R, Forgeron P, Palermo TM, Birnie KA, Anderson BJ, Chambers CT, Crombez G, Ljungman G, Jordan I, Jordan Z, Roberts C, Schechter N, Sieberg CB, Tibboel D, Walker SM, Wilkinson D, Wood C: Delivering transformative action in paediatric pain: a Lancet Child & Adolescent Health Commission. *Lancet Child Adolesc Health* 2021;5:47–87 [PubMed: 33064998]
136. Seehusen DA, Edwards J: Patient practices and beliefs concerning disposal of medications. *J Am Board Fam Med* 2006;19:542–7 [PubMed: 17090787]
137. Sandbrink F, Uppal R: The time for opioid stewardship is now. *Jt Comm J Qual Patient Saf* 2019;45:1–2 [PubMed: 30522832]
138. Institute for Safe Medication Practices Canada: Opioid stewardship. 2021 https://www.ismp-canada.org/opioid_stewardship/
139. National Quality Forum: National Quality Partners Playbook™: Opioid Stewardship. Washington DC, National Quality Forum, 2018
140. Phelps P, Achey TS, Mieure KD, Cuellar L, MacMaster H, Pecho R, Ghafoor V: A survey of opioid medication stewardship practices at academic medical centers. *Hosp Pharm* 2019;54:57–62 [PubMed: 30718936]
141. Weiner SG, Price CN, Atalay AJ, Harry EM, Pabo EA, Patel R, Suzuki J, Anderson S, Ashley SW, Kachalia A: A health system-wide initiative to decrease opioid-related morbidity and mortality. *Jt Comm J Qual Patient Saf* 2019;45:3–13 [PubMed: 30166254]
142. Barrevelde AM, McCarthy RJ, Elkassabany N, Mariano ER, Sites B, Ghosh R, Buvanendran A: Opioid stewardship program and postoperative adverse events: A difference-in-differences cohort study. *Anesthesiology* 2020;132:1558–1568 [PubMed: 32167983]
143. Ardeljan LD, Waldfogel JM, Bicket MC, Hunsberger JB, Vecchione TM, Arwood N, Eid A, Hatfield LA, McNamara L, Duncan R, Nesbit T, Smith J, Tran J, Nesbit SA: Current state of opioid stewardship. *Am J Health Syst Pharm* 2020;77:636–643 [PubMed: 32236455]
144. Brown G: Opioid stewardship: Moving beyond the “why” to the “how”. *Can J Hosp Pharm* 2020;73:3–4 [PubMed: 32109953]
145. Shishido S, Bowdle TA: Rational perioperative opioid management in the era of the opioid crisis: Comment. *Anesthesiology* 2020;133:941–942 [PubMed: 32773691]
146. Harbaugh CM, Malani P, Solway E, Kirch M, Singer D, Englesbe MJ, Brummett CM, Waljee JF: Self-reported disposal of leftover opioids among US adults 50–80. *Reg Anesth Pain Med* 2020;45:949–954 [PubMed: 33024006]
147. Sugai DY, Deptula PL, Parsa AA, Don Parsa F: The importance of communication in the management of postoperative pain. *Hawaii J Med Public Health* 2013;72:180–4 [PubMed: 23795326]
148. Holman JE, Stoddard GJ, Horwitz DS, Higgins TF: The effect of preoperative counseling on duration of postoperative opiate use in orthopaedic trauma surgery: a surgeon-based comparative cohort study. *J Orthop Trauma* 2014;28:502–6 [PubMed: 24667804]

149. Lee BH, Wu CL: Educating patients regarding pain management and safe opioid use after surgery: A narrative review. *Anesth Analg* 2020;130:574–581 [PubMed: 31567320]
150. Hasak JM, Roth Bettlach CL, Santosa KB, Larson EL, Stroud J, Mackinnon SE: Empowering post-surgical patients to improve opioid disposal: a before and after quality improvement study. *J Am Coll Surg* 2018;226:235–240 e3 [PubMed: 29331347]
151. Brummett CM, Steiger R, Englesbe M, Khalsa C, DeBlanc JJ, Denton LR, Waljee J: Effect of an activated charcoal bag on disposal of unused opioids after an outpatient surgical procedure: A randomized clinical trial. *JAMA Surg* 2019;154:558–561 [PubMed: 30916733]
152. Bicket MC, Fu D, Swarthout MD, White E, Nesbit SA, Monitto CL: Effect of drug disposal kits and fact sheets on elimination of leftover prescription opioids: The dispose multi-arm randomized controlled trial. *Pain Med* 2021;22:961–969 [PubMed: 33576394]
153. Gaunt MJ, Alghamdi D, Grissinger M: Results of the 2013-2014 opioid knowledge assessment: Progress seen, but room for improvement. *Penn Patient Safety Advisory* 2014;11:124–30
154. Petrik ML, McNamara PJ, Moeschler SM, Blair BD: Communication of recommendations for the disposal of unused prescription opioid medications by stakeholders in the news media. *Pain Med* 2019;20:1711–1716 [PubMed: 31127840]
155. US Food and Drug Administration: Where and how to dispose of unused medicines. 2021 <https://www.fda.gov/consumers/consumer-updates/where-and-how-dispose-unused-medicines>
156. Michigan Open Prescribing Network: Safe opioid disposal. 2021 <https://michigan-open.org/safe-opioid-disposal/>
157. North Carolina Medical Board: Prevent medication misuse 2021 <https://www.ncmedboard.org/landing-page/safe-medication-disposal>
158. Health Products Stewardship Association: Returning medications. 2021 <https://healthsteward.ca/returning-medications>
159. US Drug Enforcement Administration: National prescription drug take back day. 2021 https://www.deadiversion.usdoj.gov/drug_disposal/takeback/
160. Kearney M, Reynolds L, Blitzstein S, Chapin K, Massey P: Primary prevention of prescription drug misuse among culturally and linguistically diverse suburban communities. *J Community Health* 2019;44:238–248 [PubMed: 30315395]
161. Gregory T, Gregory L: The role of pharmacists in safe opioid dispensing. *J Pharm Pract* 2019;897190019852803
162. Egan KL, Gregory E, Sparks M, Wolfson M: From dispensed to disposed: evaluating the effectiveness of disposal programs through a comparison with prescription drug monitoring program data. *Am J Drug Alcohol Abuse* 2017;43:69–77 [PubMed: 27797283]
163. U.S. Department of Health and Human Services: How to safely dispose of drugs. 2021 <https://www.hhs.gov/opioids/prevention/safely-dispose-drugs/index.html>
164. Lawrence AE, Carsel AJ, Leonhart KL, Richards HW, Harbaugh CM, Waljee JF, McLeod DJ, Walz PC, Minneci PC, Deans KJ, Cooper JN: Effect of drug disposal bag provision on proper disposal of unused opioids by families of pediatric surgical patients: a randomized clinical trial. *JAMA Pediatr* 2019:e191695 [PubMed: 31233129]
165. Adler AC, Yamani AN, Sutton CD, Guffey DM, Chandrakantan A: Mail-back envelopes for retrieval of opioids after pediatric surgery. *Pediatrics* 2020;145:e20192449 [PubMed: 32051219]
166. Schuler MS, Heins SE, Smart R, Griffin BA, Powell D, Stuart EA, Pardo B, Smucker S, Patrick SW, Pacula RL, Stein BD: The state of the science in opioid policy research. *Drug Alcohol Depend* 2020;214:108137 [PubMed: 32652376]
167. National Association of Chain Drug Stores: NACDS backs “partial fill” concept to curb opioid abuse, makes recommendations to DEA for success of new rule (February 3, 2021). 2021 <https://www.nacds.org/news/nacds-backs-partial-fill-concept-to-curb-opioid-abuse-makes-recommendations-to-dea-for-success-of-new-rule/>
168. U.S. Department of Homeland Security: Opioids. 2021 <https://www.dhs.gov/opioids#>
169. White House Office of National Drug Control Policy: Biden-Harris administration’s drug policy priorities for the administration’s first year. 2021 <https://www.whitehouse.gov/ondcp/briefing-room/2021/04/01/biden-harris-administration-announces-first-year-drug-policy-priorities/>
170. Kharasch ED: Postoperative opioid prescribing and pain. *Ann Surg* 2020;271:e126

171. Srivastava D, Hill S, Carty S, Rockett M, Bastable R, Knaggs R, Lambert D, Levy N, Hughes J, Wilkinson P: Surgery and opioids: evidence-based expert consensus guidelines on the perioperative use of opioids in the United Kingdom. *Br. J. Anaesth* 2021;126:1208–16 [PubMed: 33865553]
172. Jones CM, Logan J, Gladden RM, Bohm MK: Vital signs: Demographic and substance use trends among heroin users - United States, 2002-2013. *MMWR Morb Mortal Wkly Rep* 2015;64:719–25 [PubMed: 26158353]
173. Hartung DM, Geddes J, Johnston KA, Leichtling G, Hallvik S, Hildebran C, Korthis PT: Patterns of prescription opioid use prior to self-reported heroin initiation. *J Addict Med* 2021;15:130–133 [PubMed: 32732683]
174. US Drug Enforcement Administration: National Drug Threat Assessment, DEA-DCT- DIR-008-21. 2021 www.dea.gov/sites/default/files/2021-02/DIR-008-21 2020 National Drug Threat Assessment_WEB.pdf
175. Park JN, Rashidi E, Foti K, Zoorob M, Sherman S, Alexander GC: Fentanyl and fentanyl analogs in the illicit stimulant supply: Results from U.S. drug seizure data, 2011-2016. *Drug Alcohol Depend* 2021;218:108416 [PubMed: 33278761]
176. Mogil JS: Sources of individual differences in pain. *Annu Rev Neurosci* 2021;44:1–25 [PubMed: 34236890]
177. National Institute on Drug Abuse: Overdose death rates. 2021 <https://www.drugabuse.gov/drug-topics/trends-statistics/overdose-death-rates>
178. US Drug Enforcement Administration: Partial filling of prescriptions for schedule II controlled substances. Federal Register [Docket No. DEA-469] RIN 1117-AB45 2021 https://www.deadiversion.usdoj.gov/fed_regs/rules/2020/fr1204_2.pdf
179. American College of Surgeons: Patient education initiatives: Safe pain control: Opioid abuse and surgery. 2018 <https://www.facs.org/education/opioids/patient-ed>
180. Michigan Opioid Prescribing Network: Opioids and pain management. 2021 <https://michigan-open.org/wp-content/uploads/2020/11/Surgical-READY-TO-PRINT-non-prof-print.pdf>
181. Soffin EM, Lee BH, Kumar KK, Wu CL: The prescription opioid crisis: role of the anaesthesiologist in reducing opioid use and misuse. *Br J Anaesth* 2019;122:e198–e208 [PubMed: 30915988]
182. Hilliard PE, Waljee J, Moser S, Metz L, Mathis M, Goesling J, Cron D, Clauw DJ, Englesbe M, Abecasis G, Brummett CM: Prevalence of preoperative opioid use and characteristics associated with opioid use among patients presenting for surgery. *JAMA Surg* 2018;153:929–937 [PubMed: 29998303]
183. Edwards DA, Hedrick TL, Jayaram J, Argoff C, Gulur P, Holubar SD, Gan TJ, Mythen MG, Miller TE, Shaw AD, Thacker JKM, McEvoy MD: American society for enhanced recovery and perioperative quality initiative joint consensus statement on perioperative management of patients on preoperative opioid therapy. *Anesth Analg* 2019;129:553–566 [PubMed: 30768461]
184. Rishel CA, Angst MS, Sun EC: Preoperative opioid utilization patterns and postoperative opioid utilization after surgery: A retrospective cohort study. *Anesthesiology* 2021 in press
185. Sritapan Y, Clifford S, Bautista A: Perioperative management of patients on buprenorphine and methadone: A narrative review. *Balkan Med J* 2020;37:247–252 [PubMed: 32407063]
186. Goel A, Azargive S, Lamba W, Bordman J, Englesakis M, Srikandarajah S, Ladha K, Di Renna T, Shanthanna H, Duggan S, Peng P, Hanlon J, Clarke H: The perioperative patient on buprenorphine: a systematic review of perioperative management strategies and patient outcomes. *Can J Anaesth* 2019;66:201–217 [PubMed: 30484167]
187. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, Ferri M, Pastor-Barriuso R: Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. *BMJ* 2017;357:j1550 [PubMed: 28446428]
188. Kharasch ED, Clark JD: Methadone and ketamine: Boosting benefits and still more to learn. *Anesthesiology* 2021;134:676–679 [PubMed: 33740051]
189. Ilfeld BM, Plunkett A, Vijjeswarapu AM, Hackworth R, Dhanjal S, Turan A, Cohen SP, Eisenach JC, Griffith S, Hanling S, Sessler DI, Mascha EJ, Yang D, Boggs JW, Wongsarnpigoon A, Gelfand H: Percutaneous peripheral nerve stimulation (neuromodulation) for postoperative

pain: A randomized, sham-controlled pilot study. *Anesthesiology* 2021;135:95–110 [PubMed: 33856424]

190. Kharasch ED: Intraoperative methadone: rediscovery, reappraisal, and reinvigoration? *Anesth Analg* 2011;112:13–6 [PubMed: 21173206]
191. Komen H, Brunt LM, Deych E, Blood J, Kharasch ED: Intraoperative methadone in same-day ambulatory surgery: A randomized, double-blinded, dose-finding pilot study. *Anesth Analg* 2019;128:802–810 [PubMed: 29847382]
192. Murphy GS, Szokol JW: Intraoperative methadone in surgical patients: A review of clinical investigations. *Anesthesiology* 2019;131:678–692 [PubMed: 31094758]
193. Murphy GS, Avram MJ, Greenberg SB, Shear TD, Deshur MA, Dickerson D, Bilimoria S, Benson J, Maher CE, Trenk GJ, Teister KJ, Szokol JW: Postoperative pain and analgesic requirements in the first year after intraoperative methadone for complex spine and cardiac surgery. *Anesthesiology* 2020;132:330–342 [PubMed: 31939849]
194. Murphy GS, Avram MJ, Greenberg SB, Benson J, Bilimoria S, Maher CE, Teister KJ, Szokol JW: Perioperative methadone and ketamine for postoperative pain control in spinal surgical patients: A randomized, double-blind, placebo-controlled trial. *Anesthesiology* 2021;134:697–708 [PubMed: 33730151]

Text Box 1**Partial filling of opioid prescriptions**

1. Partial filling of prescriptions for a schedule III, IV, or V controlled substances. This is currently permitted (21 CFR Part 1306.23), provided that the total quantity dispensed in all partial fillings does not exceed the total quantity prescribed, no dispensing occurs later than 6 months after the initial prescription, and each partial filling is properly recorded
2. Partial filling of prescriptions for a schedule II controlled substances. The Comprehensive Addiction and Recovery Act of 2016 amended the Controlled Substances Act (21 U.S.C. 829, new paragraph f) to allow partial filling of prescriptions for schedule II controlled substances, when requested by a patient or practitioner. Additional requirements are that partial filling is not prohibited by state law, the total quantity dispensed in all partial fillings does not exceed the total quantity prescribed, and no dispensing occurs later than 30 days after the initial prescription (unless it was an emergency oral prescription, in which case the remaining portion must be filled within 72 hr).

In December 2020, the Drug Enforcement Administration issued a Notice of Proposed Rulemaking (Docket No. DEA-469) to modify the Code of Federal Regulations (21 CFR Part 1306) to revise the DEA regulations to incorporate the new statutory provisions.¹⁷⁸

Where a practitioner requests that a schedule II prescription be partially filled (as the Comprehensive Addiction and Recovery Act now allows), the proposed rule states that the face of the written prescription must specify the quantity to be dispensed in the partial filling.

Where a patient requests that a schedule II prescription be partially filled (as the Comprehensive Addiction and Recovery Act now allows), the proposed rule states that the pharmacy would be required to indicate on the prescription that the patient requested the partial fill. One caveat is that where a practitioner has requested the partial filling of a prescription, the patient may not request a partial filling in an amount greater than that specified by the practitioner. A patient request to the pharmacy for a partial fill would not require the consent of, or notification of, the prescribing practitioner.

In addition, DEA recognized that many post-surgery patients may have a difficult time visiting a pharmacy in person, therefore the proposed rule would not require an in-person request by the patient in every case and would allow alternative pathways for the patient to make such a request and specify the amount to be filled (e.g., phone call by the patient to the pharmacist, or a signed written note from the patient and delivered by a family member to the pharmacist).

Text Box 2.**Perioperative practitioner engagement in the prescription opioid ecosystem**

Anesthesiologists and surgeons engage multiple facets of the perioperative opioid ecosystem. Anesthesiologists can have prominent roles in each step or even comprehensively oversee the process. Postoperative opioid needs (demand) can be diminished by optimized intraoperative/PACU anesthesia care, opioid supply can be more carefully managed, consumption reduced by education about expectations and alternatives, and opioid stewardship enhanced by education about storage, disposal, and return.

Educate patients pre- and post-operatively on pain, pain management, and opioid use

Establishment of a therapeutic alliance between patients, anesthesiologists and surgeons is needed, with clear expectation as to who will provide the needed education. Perioperative education is often completely missing, but even when present may inadequately set expectations for pain relief, incompletely outline the use of opioids as one tool amongst many to control pain, and fail to review risks and proper handling of leftover opioids.¹⁴⁹ Educational materials are immediately and publically available (cf “Safe and Effective Pain Control After Surgery” from the American College of Surgeons,¹⁷⁹ and “Opioids and Pain Management” from the Michigan Opioid Prescribing Engagement Network,¹⁸⁰ Preoperative education may reduce postoperative pain scores and opioid use,¹⁴⁷ or hasten opioid cessation.¹⁴⁸ Patient education supervised by anesthesiologists should be a key component of a comprehensive perioperative opioid use and risk reduction strategy.¹⁸¹

Educate patients pre- and post-operatively on opioid stewardship, storage and disposal

Preoperative anesthesia assessments, discharge planning, and outpatient PACU and inpatient ward discharge visits afford opportunities to educate patients and caregivers whose focus is undistracted and attuned. Topics should include pain expectations, opioid and non-opioid analgesics and optimal use, avoidance of dangerous opioid drug interactions, proper storage of unused opioids, the idea that opioids are “loaned” not “given”, and the need for proper disposal or return (“give-back”) and the responsible and effective methods for doing so, as well as the benefit to them and society. There is also the need to educate the educators.

Evaluate patient preoperative opioid use

Consider preoperative opioid tapering for patients on chronic opioids. Chronic preoperative opioid use is common,¹⁸² and a risk factor for worse surgical outcomes, surgical complications, poor pain control, greater suffering, opioid-related respiratory depression, perioperative dose escalation and prolonged postoperative opioid use, longer length of stay, greater costs, more frequent readmissions, and more difficult to control postoperative pain.^{183,184} Tapering preoperative opioids has been suggested, with less

acute and chronic postoperative pain and opioid consumption and enhanced functional recoveries among the hoped-for outcomes.¹⁸³ Unfortunately, it is simply not known for whom and to what degree preoperative opioid taper is appropriate, and there exists limited evidence for the effectiveness of tapering and few successfully proven protocols,¹⁸³ and recent evidence that reducing opioid use preoperatively did not result in lower postoperative opioid use.¹⁸⁴ In addition, there may be risks. Opioid discontinuation, whether abrupt or with dose reduction significantly increased risk of suicide (hazard ratio 4-5), and patients with abrupt discontinuation were more likely than others to overdose on heroin (vs prescription opioids).¹⁰⁰ Discontinuation of long-term opioids was associated with a 3-fold greater risk of overdose death.⁹⁷ Shorter time to discontinuation was associated with greater risk of opioid-related adverse events⁹⁸

Identify patients with opioid use disorder. First consideration should be given to stabilizing patients by referral for medication assisted treatment, counseling, support, and other evidence-based interventions. Under-treatment of opioid use disorder, inadequate availability of treatment, and under-utilization of and access to medication-assisted therapies such as methadone and particularly buprenorphine, is well-known. Those having more urgent surgery should have opioid use gauged, and surgical and anesthesia teams notified in order to optimize care. Patients on medication assisted treatment will require that to be managed, generally with continuation throughout the perioperative period (definitely methadone, although buprenorphine is more controversial and with limited evidence).^{185,186} Discontinuation of medication assisted treatment may confer critical risks of return to illicit drug use or overdose.¹⁸⁷

Implement evidence-based anesthesia which confers benefit and reduce risk.

Use patient-specific intraoperative and PACU anesthetic regimens which provide excellent perioperative pain relief, optimize patient recovery trajectory, minimize post-discharge pain and opioid requirements, and ideally confer continued and long-term benefit after discharge.⁵⁸ Remember that the majority (80%) of surgical patients report in adequately pain treatment,^{45,105-107} acute surgical pain causes suffering, diminished patient satisfaction, and is associated with surgical complications and regret,^{42,108-111} and is a major risk factor for chronic postoperative pain and persistent postoperative opioid use.^{101,112-117} Opioids are the most efficacious systemic analgesics available for moderate-severe pain. Multimodal approaches may have benefit and spare opioids, when evidence-based. Choose strategies that maximize pain control while minimizing the need for postoperative discharge oral opioids and associated potential long-term harms.¹⁰¹ Adequate analgesia, not withholding needed opioids, should be the primary goal.¹³² Opioid-sparing by itself is not likely meaningful to patients unless accompanied by improved patient-centric outcomes like better pain relief or the sparing of undesirable opioid-related side effects.¹⁸⁸ Opioid-free anesthesia has not been shown to have benefits beyond opioid-sparing strategies, to influence or prevent persistent postoperative opioid use, or to prevent postoperative opioid overprescription.^{91,94} Regional anesthesia and other non-opioid multimodal strategies generally reduce postoperative pain opioid requirements for several hours to days; catheter-based systems can extend benefits of some blocks for a week or more. Newer techniques of percutaneous neuromodulation may be promising.¹⁸⁹ Current approaches need improvement. Multimodal analgesia

decreases acute but not chronic postoperative pain,¹²² Epidural anesthesia may not protect against persistent opioid use,¹²⁴ Nerve block for total knee or shoulder arthroplasty did not decrease persistent postoperative opioid use,^{126 125} and perioperative gabapentinoids have no effect on chronic postoperative pain¹²⁷ Intraoperative methadone, with or without ketamine, for some inpatient and outpatient procedures, can result in less postoperative pain and opioid use, with benefits that last for weeks to months.^{190–194}

Right-size post-discharge oral opioid prescriptions

Postoperative patients should ubiquitously receive non-opioid analgesics, but may experience moderate-severe pain needing opioids. Adequate postoperative pain treatment is imperative, and fundamental for preventing conversion from acute to chronic pain.¹¹⁴ Opioid-sparing and multi-modal techniques may reduce immediate perioperative opioid needs, but little patient benefit accrues if discharge opioid amounts are not tailored, and particularly if under- or over-prescribed. Withholding needed opioids is not appropriate. Interindividual variability in pain severity and duration and analgesic response confounds one size fits all postdischarge oral opioid prescribing. Communication with surgical teams about appropriate discharge opioids while adding non-opioid analgesics, taking responsibility, where possible, for designing and implementing opioid-sparing discharge analgesic plans, and arranging transitional pain management care are all responsibilities anesthesia groups and acute pain services might assume. Commensurate with responsibility for proper opioid prescribing is patient education about opioid stewardship, safe use, storage, disposal and return of unused opioids.

Consider implementing transitional pain management

This addresses the period between discharge and the re-establishment of care with the patient's primary provider, for patient care and education about postoperative pain, opioids and other pain drugs, opioid stewardship, and opioid return/disposal. The first transitional pain service was developed to reduce chronic postsurgical pain by identifying high risk patients and providing coordinated and comprehensive care from a multidisciplinary team of pain physicians, psychologists, physiotherapists, and advanced practice nurses.¹²⁸ Patients are seen preoperatively, postoperatively or as outpatients for up to 6 months after surgery. A service can bypass potentially long waiting times for postoperative patients to be referred and seen in chronic pain clinics. Expanded aims are to reduce opioid consumption in preoperatively opioid-naïve and opioid-experienced patients.^{129,130} Services may include opioid, non-opioid and multimodal analgesia management to improve pain and opioid weaning, non-pharmacologic interventions including acupuncture and physiotherapy, and psychological interventions around pain education and coping.¹³⁰ May enhance communication between surgical team, primary providers, and chronic pain specialists, and is amenable to telehealth implementation.

US opioid overdose deaths & opioid prescribing

The opioid paradox




Figure 1.

The Opioid Paradox. Opioid prescriptions are declining while opioid overdose deaths are increasing. Data source: References ^{30,38,177}

Prescription Opioid Ecosystem




Figure 2.

The prescription opioid ecosystem. The pool of unused prescription opioids available for diversion, misuse and overdose is influenced by supply, demand, and return or disposal. Overprescription of opioids, while providing sufficient supply to treat pain, risks potential patient overuse or residual unused opioids, and underprescription risks undertreated acute and chronic pain. Reducing supply alone has not been successful at reducing opioid overdose rates. Reducing demand through better pain treatment, and enhancing disposal and return, are additional approaches to reducing the opioid pool and mitigating opioid misuse and overdose deaths.




Figure 3.

Analytic framework for prescribing opioids for acute pain and evidence linkages necessary to support the development of clinical practice guidelines for opioid prescribing. The framework begins with the patient population with acute pain (e.g., postoperative pain). The wide arrow indicates evidence evaluating the effects of an opioid prescribing strategy on a health or intermediate outcome. The dotted lines indicate linkages between different outcomes (e.g., association between a lesser amount of opioid used and risk of long-term use or quality of life), not between an intervention and an outcome (or, in the case of intermediate outcomes and long-term opioid use, between one intermediate and another intermediate outcome). Short- and long-term health outcomes, both beneficial and harmful, may be seen at the patient and community or population levels. Reproduced from *Framing Opioid Prescribing Guidelines for Acute Pain: Developing the Evidence*⁴⁴ with permission of the National Academy of Sciences, Courtesy of the National Academies Press, Washington, D.C.

Surgery and opioids: Opioid safety and stewardship




Figure 4. Surgery and opioids: Opioid safety and stewardship. Includes some information from Srivastava et al.¹⁷¹